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ABSTRACT

Tauopathies are neurodegenerative diseases that affect millions of people around
the world. Tauopathies include more than 20 neurodegenerative diseases. Some of the
most common tauopathies are Alzheimer’s disease (AD), frontotemporal dementia (FTD),
chronic traumatic encephalopathy (CTE), Pick’s disease, corticobasal degeneration,
progressive supranuclear palsy (PSP), agyrophillic grain disease, and amyotrophic lateral
sclerosis (ALS). These diseases can cause significant memory loss, behavioral changes,
motor deficits and speech impairments. Tauopathies stem from accumulation of the
microtubule associated protein tau (MAPT). Tau stabilizes microtubules and helps with
axonal transport. In a disease state tau becomes hyperphosphorylated and truncated
leading to its aggregation. More recently tau has been shown to propagate from cell to
cell potentially acting as a signaling molecule that contributes to disease progression. In
addition during disease, tau mislocalizes to dendrites leading to synaptic dysfunction. This
mislocalization may also lead to subsequent neurodegeneration.
Today, many strategies have been implemented to treat tauopathies. Some of
these strategies include kinase inhibitors, immunotherapy, tau aggregation inhibitors, and
microtubule-stabilizing compounds. However none these strategies have been effective
in stopping tau pathology nor do they address tau degradation pathways. Therefore we
hypothesized that utilizing small molecules that target degradation pathways such as
autophagy or proteasomal degradation would improve clearance of aberrant tau.
vii

We previously showed that a natural product (+)-aR,11S-myricanol (1) from
Myrica cerifica (bayberry/southern wax myrtle) root bark reduced levels of tau. In this
study we discovered that 1 is composed of two enantiomers and two possible
atropisomers. We found that one enantiomer (-)-aS,11R-myricanol (3) was responsible
for the anti-tau activity of 1 in multiple models of tauopathy. We also found that 3
selectively targets and lowers specific tau species. To better understand how these tau
species were being reduced we took a non-biased approach and subjected 3 treated
samples to stable isotope labeling by amino acids in cell culture (SILAC) mass
spectrometry (MS) proteomic analysis. We found that autophagy pathways were most
affected by 3 and that 3 was predicted to mimic the drug rapamycin, a well-established
macroautophagy activator. In addition we confirmed our MS findings by simultaneously
giving 3 treated cells an autophagy inhibitor which blocked 3’s tau reductions. Moreover
we created a tetralin derivative of 1, 13, that produced the same effects on tau as 3 but
did not rely upon stereochemistry for its activity. This work supports targeting the
autophagy degradation pathway as a viable approach to improving aberrant tau
accumulation.
In order to further support our hypothesis, we collected and screened several
known heat shock protein 70 (Hsp70) inhibitors and tau aggregation inhibitors for cellular
anti-tau activity. While it is known that Hsp70 inhibition facilitates tau clearance through
proteasomal degradation, it is not known what role tau aggregation inhibition plays in the
cellular degradation of tau. Moreover understanding which inhibitory activity contributes
most to tau degradation would lead to the creation of better drug scaffolds. In this study,
we found that several Hsp70 inhibitors from different scaffold backbones had varying

viii

effects on tau degradation. The rhodacyanine and phenothiazine compounds were most
effective

at lowering

cellular

tau

while the adenosine

analog,

sulfonamide,

dihyropyrimidine, piperidine-3-carboxamide, phenoxy-N-arylacetamide, and flavonol,
were not as effective. We also examined the effects of several tau aggregation inhibitor
scaffolds such as the carbocyanine, oleuropein, anthraquinone, aminothienopyridazine,
hydroxytyrosol and rhodanine on tau expression reduction. We found that none had
effective tau reductions except the carbocyanine. However when we performed a lactate
dehydrogenase (LDH) assay, carbocyanine was shown to be extremely toxic. These
results lead us to further investigate if the tau expression reducing Hsp70 inhibitors had
anti-tau aggregation activity and if the tau aggregation inhibitors had any Hsp70 inhibitory
activity. We discovered that many of the Hsp70 inhibitors also had anti-tau aggregation
activity while none of the aggregation inhibitors had Hsp70 inhibitory activity. We found a
positive correlation between tau expression reductions and anti-tau aggregation activity
for the Hsp70 inhibitors. Our work demonstrates that both Hsp70 activity and tau
aggregation in vitro best predicts anti-tau activity of small molecules. Also these dual
acting Hsp70 inhibitors support our hypothesis that targeting the degradation pathways
can improve tau clearance.
Overall, this work indicates the importance of targeting degradation pathways to
improve tau clearance. Utilizing small molecules that have dual activities against tau could
prove beneficial as a novel therapeutic approach to treat tauopathies. In addition using
small molecules that target different degradation pathways simultaneously could be
another viable therapeutic strategy for treatment of tauopathies.

ix

CHAPTER ONE:
RATIONALE FOR TARGETING TAU DEGRADATION FOR TREATMENT OF
TAUOPATHIES
1.1 Tau Biology
Tau is an intrinsically disordered cytosolic 441 amino acid (aa) protein which binds
to microtubules and promotes microtubule assembly.1 It is mainly located in the axons of
neurons found in the central and peripheral nervous systems.1 As a result tau can regulate
axonal transport.1-3 More specifically tau can help motor proteins detach their cargo to
increase axonal transport efficiency. In contrast tau can also inhibit kinesin and dynein
trafficking to prevent axonal transport to the synapse.4, 5 Another function of tau is that it
can bind and bundle actin filaments which can lead to neurodegeneration.6 Also more
recently tau has been thought to be an external signaling molecule.3 Tau has been shown
to be released into the extracellular space from healthy or dying neurons allowing it to
propagate to neighboring cells like a prion.7-10 In disease tau mislocalizes to the dendritic
compartment of the neuron.11-13 Many in the field believe this and its subsequent release
act to progress disease as well send signals to neighboring cells. However the
mechanism of tau release has remained elusive but our lab and others have suggested
tau may be released by SNARE mediated exocytosis or exosomal release.14,

15

This

phenomenon has caused tau to become a major drug target in multiple diseases termed
tauopathies. Tauopathies are neurodegenerative diseases that develop from the
abnormal accumulation of tau. Two of the most prevalent tauopathies are AD and FTD.16
1

In both AD and FTD patients experience memory loss, behavioral changes, motor deficits
and speech impairments.16 Despite these diseases being so common, there are no
treatments that stop the pathology. Therefore a better understanding of what role tau
plays in these diseases and how to prevent its accumulation and release could provide
new therapeutic approaches to treat tauopathies.
Genetically, tau is located in locus 17q21.3.17 Tau has 16 exons three of which are
alternatively spliced (exons 2, 3, and 10) in the central nervous system to generate six
isoforms; 4R2N, 4R1N, 4R0N, 3R2N, 3R1N, or 3R0N tau.17 Additionally in the peripheral
nervous system exon 4A is included in tau to form the largest form of tau known as “Big
Tau”.18 In these isoforms R represents the number of repeats domain while N represents
the number of N-Terminal inserts. Exons 2 and 3 correspond to tau’s N-Terminal inserts
and exon 10 to the second region of tau’s microtubule binding repeat domain.17 These NTerminal inserts are part of the projection domain that allows tau to interact with the cell
membrane.19 In addition tau has four microtubule binding repeat domains (MBD).17
These domains are composed of a KXGS conserved motif with the positively charged
amino acid lysine (K), which helps allow tau to bind to the negatively charged
microtubules. In adult humans the most common isoform is 4R0N tau while 3R0N tau is
the most common in the fetal brain.20 Alterations in the ratio of 4R0N to 3R0N can lead to
disease.20 In addition, tau may undergo a variety of post-translational modifications such
as ubiquitination, glycation, nitration, sumolyation, glycosylation, isomerization,
methylation, acetylation, polyamination, oxidation, truncation and most notably
phosphorylation.17 Tau has approximately 85 putative phosphorylation sites. There are
45 serines, 35 threonines, and 5 tyrosines sites. Moreover several kinases phosphorylate
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tau. Some of these include glycogen synthase kinase-3β (GSK3β), cyclin-dependent
kinase-5 (CDK5), mitogen-activated protein kinase (MAPK), casein kinase 1 (CK1), dualspecificity tyrosine phosphorylation and regulated kinase 1A (DYRK1A), microtubule
affinity-regulating kinases (MARKs), protein kinase cyclic adenosine monophosphate
(cAMP)-dependent, protein-tyrosine kinase Fyn (Src Kinase) and Ca2+/calmodulindependent protein kinase II (CaMKII). With this in mind, phosphorylation of tau’s serines
in the MBD can lead to decreased binding to the microtubule which in turn can lead to the
hyperphosphorylation of tau.17 Tau hyperphosphorylation is defined as a rise in the
number of sites phosphorylated and/or as an increase in the number of tau molecules
phosphorylated.17 Additionally, hyperphosphorylation of tau can be caused by mutations
in tau or pathological events that cause microtubule destabilization such as amyloid β
misprocessing. There are more than 50 mutations that have been found in tau which have
been associated with disease. More importantly, mutations found in the microtubule
binding

region

such

as

P301L,

V337M,

and

G303V

can

lead

to

tau

hyperphosphorylation.21 In addition axonal injury from traumatic brain injury (TBI) and
degradation pathway misprocessing can cause the hyperphosphorylation of tau.22-26 Most
importantly the hyperphosphorylation of tau leads to the formation of toxic aggregates.17
Tau aggregation is the main hallmark of many tauopathies.

1.2 Tau Aggregation
Tau aggregation occurs in a multistep process after the hyperphosphorylation of
tau. Soluble hyperphosphorylated tau molecules (tau monomer) first dimerize with each
other to form dimers. Next the dimers polymerize to form oligomers. The oligomers then

3

assemble to form protomers.17 These protomers then organize into insoluble paired
helical filaments (PHFs). The PHFs then mature into neurofibrillary tangles (NFTs) which
are the most common biomarker in tauopathies such as AD, CTE, and FTD.27, 28 Moreover
tau can aggregate through self-aggregation or binding to native tau not bound to
microtubules. One way in which these aggregates form is tau having two naturally
occurring cysteine residues located in the microtubule binding domain. These cysteines
allow tau to form intermolecular disulfide bonds with neighboring tau molecules leading
to tau aggregates.29-32 Another way in which these aggregates form is through the
interaction of two hexapeptide motifs found in the second and third MBD of tau. The motifs
275

VQIINK280 and 306VQIVYK311 interact through hydrogen (H) bonding between separate

tau molecules.33 In addition there is a tyrosine(Y)-tyrosine aromatic interaction which
stabilizes the β-sheets to allow the formation of the PHFs. While mature PHFs, NFTs,
were once perceived to be the toxic species causing neuronal cell death, it is now believed
that tau oligomers cause neuronal cell death. Evidence has been given showing NFTs to
be neuroprotective in multiple models of disease.34-36 The formation NFTs is a possible
mechanism to avoid neurotoxicity. Hyperphosphorylated tau alone disrupts normal tau
function

of

microtubule

assembly

and

causes

cell

death.20

However

when

hyperphosphorylated tau polymerizes to form NFTs, disruption of microtubule assembly
cannot occur.20 Therefore an intermediate form of tau, tau oligomers, have been reported
to cause microtubule depolymerization and neurodegeneration.37,

38

In addition many

studies have suggested that the main form of tau released and transmitted to neighboring
cells is oligomeric tau.20, 37-40 With this in mind, there is a need for a better understanding
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of how to improve tau degradation to prevent oligomer formation and subsequent tau
pathology.

1.3 Tau Degradation
Many studies have shown that tau is degraded through the ubiquitin-proteasome
system (UPS) and the autophagy-lysosomal system. The ubiquitin-proteasome system
regulates and maintains protein levels by abolishing mutant, misfolded or damaged
proteins.41

There are two pathways for the UPS; ubiquitin (Ub) dependent or Ub

independent. In the Ub dependent pathway proteins’ lysines are covalently conjugated to
an ubiquitin molecule or a chain of ubiquitin molecules.41, 42 The chain of Ub is then
recognized by the proteasome. Once recognized the protein is passed through the
proteasome and proteolysed by trypsin-like, chymotrypsin-like, and post-glutamyl
activities into small proteolytic fragments.41,

42

In comparison in the Ub independent

pathway substrate proteins are able to proceed directly to the proteasome for
degradation.41, 42 Tau can proceed through both UPS pathways.42 More specifically, full
length monomeric tau is degraded through the UPS while truncated and insoluble forms
of tau go through the autophagy-lysosomal system.42, 43 Originally, tau pathology was
thought to be caused by full length tau forming paired helical filaments (PHFs). Studies
showed that PHFs were ubiquitinated at three main sites in the MBD which are K254,
K311, and K353.42 Studies also showed that when the proteasome is blocked by highly
ubiquitinated tau PHFs this could cause cell death and neurodegeneration.42 These
ubiquitinated PHFs obstruct the proteasome and make degradation of proteins inefficient.
This evidence led the field to believe that the misprocessing of ubiquitin-proteasome
system was the only cause of tau pathology. However more recently cleaved/truncated
5

forms of tau have been shown to create toxic oligomers.44,

45

In addition autophagic

processing has been shown to decrease with age and in diseased states.24, 46, 47 This led
the field to more closely investigate the role of autophagy in tau degradation. Unlike
proteasomal

degradation

there

are

three

major

pathways

for

autophagy;

macroautophagy, microautophagy, and chaperone mediated autophagy (CMA). All three
autophagy pathways involve the lysosome lysing substrate proteins, fragments or other
cytoplamsic cellular debris.48 More specifically in macroautophagy, the target proteins are
engulfed by a phagophore which then becomes an autophagosome that fuses with the
lysosome.48 The newly formed autolysosome then lyses its contents. In comparison in
microautophagy, invagination of the lysosomal membrane allows cytoplasmic
components to enter and then be degraded.48 For CMA on the other hand, substrates are
bound to chaperones and escorted to the lysosome for degradation.48 For tau,
macroautophagy and CMA have been shown to be most commonly involved in its
degradation.25 More specifically the Mandelkow group published that chaperone
mediated autophagy creates cleaved forms of tau or tau fragments which can seed the
formation of tau oligomers.45 This occurs by the chaperone, heat shock protein cognate
70 (Hsc70), recognizing the pentapeptide lysosomal targeting motifs in tau (336QVEVK340
and

347

KDRVQ351) and then translocating tau through the lysosome-associated

membrane protein type 2A (LAMP-2A).45, 49 During the translocation tau becomes stuck
in the membrane and is cleaved by lysosomal proteases, mainly the cathepsins D and
L.45, 50 These proteases generate multiple fragments inside and outside the lysosomal
membrane. The outside fragment most associated with the lysosomal membrane has
been hypothesized to then seed the formation of tau oligomers in the cytosol.45 In addition
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they

suggested

that

these

aggregates

could

be

degraded

by

subsequent

macroautophagy activation. They showed that if you block macroautophagy by chemical
inhibition tau will aggregate and cause cellular toxicity.25,

51

Furthermore our lab has

shown that Hsc70 rapidly engages tau after microtubule destabilization and increases tau
accumulation.52 This increase in tau accumulation could be due to CMA misprocessing
of tau.53 Thus developing better tools that can divert tau away from Hsc70 and CMA by
stimulating proteasomal degradation or macroautophagy will provide more effective
treatments for stopping tau pathology.

1.4 Tau Therapeutics
Currently, there are not many effective treatments for people who suffer from
tauopathies in particular AD. Current treatments for AD include acetylcholinesterase
inhibitors, acetylcholine agonists, and glutamatergic antagonists.54 While these palliative
medications help lessen the symptoms, they do not address the underlying cause of the
disease or stop disease progression. Patients also spend around $177 to more than $400
per month on medications.54 As a result more experimental strategies have been
investigated to find better treatments for AD and other tauopathies. These current
strategies include tau kinase inhibitors, tau immunotherapy, microtubule stabilizers, tau
aggregation inhibitors, and small molecules targeting tau degradation.55 More specifically,
kinase inhibitors have been used to reduce the hyperphosphorylation of tau and
subsequent formation of neurofibrillary tangles. Inhibitors targeting the tau kinases GSK3β, PKC, Fyn (Src Kinase), and others have shown decreases in tau pathology.56-64 Some
have been used in clinical trials and been well tolerated by patients. However many have
concerns of potential debilitating side effects from inhibiting a kinase that phosphorylates
7

other clients besides tau.55 Another strategy that has been implemented to treat
tauopathies is immunotherapy.61 Active and passive immunotherapy utilizing antibodies
has been used to remove pathological forms of tau.60 Antibodies targeting specific
phosphorylated tau species, tau aggregates, and tau oligomers have improved cognitive
deficits in mice.38, 39, 65-68 However this strategy has shown safety concerns due to the fact
that the phosphorylated tau species are not exclusive to the AD brain but also found in
normal human brains.69 Therefore removing tau as seen in tau knockout mice can cause
deleterious motor deficits, learning impairments and memory loss.70, 71 Another strategy
used to treat tauopathies are tau aggregation inhibitors. There are several classes of tau
aggregation inhibitors including the rhodanines, phenothiazines, carbocyanines,
polyphenols, aminothienopyridazines, and anthraquinones.72-77 Anthraquinones such as
emodin, daunorubicin and adriamycin target tau aggregates to prevent paired helical
filament formation and cause PHF disassembly.77-79 However some tau aggregation
inhibitors including the anthraquinones do not reduce monomeric soluble tau levels, which
can potentially lead to the formation of toxic tau aggregates.80 Another relatively novel
strategy to treat tauopathies is the use of microtubule stabilizing agents. Chemical
compounds such as taxanes, epothilones, and pelorusides have been shown to stabilize
microtubules in various models.81,

82

Two compounds in particular paclitaxel and

epothilone D have been evaluated in animal models and have exhibited the most potential
for clinical studies.81, 82 However many of the microtubule stabilizers may have frequent
adverse side effects including increased cytotoxicity.55
One last explorative strategy that has been implemented has been to control the
protein quality control machinery to enhance tau degradation. In particular, our group
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and others have demonstrated that compounds targeting chaperones specifically heat
shock proteins (Hsps) can reduce tau levels via the ubiquitin-proteasome system.83-86 Our
lab has focused on these small molecules targeting Hsp70 family of proteins. The Hsp70s
are 70 kilodaltons (kDa) molecular chaperones that help refold, degrade, and transport
misfolded substrates/proteins such tau, α-synuclein, and TDP-43.87-90 Chaperones are
upregulated and expressed when the cell undergoes an elevation in temperature or
increase in stress.91 The Hsp70 family contains over 10 different isoforms which are
located in various organelles in the cell and can be either stress-inducible or constitutively
expressed.91 Our lab has shown that different isoforms of Hsp70, most notably the stressinducible form Hspa1A (Hsp72) and the constitutively expressed form Hspa8 (Hsc70),
have differing effects on tau. Hsp72 reduces tau accumulation with the recruitment of the
carboxyl terminus of the Hsc70-interacting protein (CHIP).92 CHIP acts as an E3 ubiquitin
ligase and helps Hsp72 triage tau for proteasomal degradation.92 On the other hand
Hsc70 preserves tau and slows its clearance possibly through CMA.92 While these
isoforms have different effects on tau they and the rest of the Hsp70 family utilize
adenosine triphosphate (ATP) to perform their functions. Most Hsp70s have three
domains: an amino-terminal ATPase domain also known as the ATP-binding domain, the
peptide or substrate binding domain and a carboxyl-terminal domain also known as the
lid domain.91, 93 In the cellular environment Hsp70s first exist in an open confirmation or
low affinity state with ATP bound in the ATPase domain.94 In this state Hsp70 substrates
are allowed to become bound or unbound to Hsp70’s substrate binding domain. Once the
Hsp70 is ready to perform its function on a bound substrate, it utilizes its intrinsic ATPase
activity and recruits other heat shock proteins such as Hsp40/DnaJ also known as a
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cochaperone to form a complex and help hydrolyze the ATP.94 This then changes the
conformation of the Hsp70 to a closed or high affinity state with ADP bound.94 In addition
the lid domain encloses the substrate for tight binding.94 The Hsp70 then carries out its
function and it forms another complex with a cochaperone known as a nucleotide
exchange factor (NEF) to help remove the ADP and then replace with ATP in order to
repeat the cycle.94 The small molecule inhibitors targeting the Hsp70s specifically prevent
the hydrolysis of ATP to ADP and the subsequent conformational change that allows the
Hsp70s to carry out their functions. Many Hsp70 inhibitor scaffolds have been created
that mimic ATP and act as a competitive inhibitor in the ATP pocket.95, 96 More common
Hsp70 inhibitor scaffolds act as allosteric modulators and bind outside the ATP pocket.84,
86, 97-101

Others have been suggested to directly interact with the DnaJ to prevent the

stimulation of Hsp70’s ATPase activity.102 One last group of inhibitors have been shown
to bind in the substrate binding domain and prevent interaction of the substrate with the
Hsp70.103 In addition all of these compounds may be also able to prevent Hsc70 CMA
facilitated tau aggregation, a potential effect which has yet to be investigated. More
specifically compounds, YM-01, JG-98 and other members of the rhodacyanine family
potently inhibit the Hsp70 family of proteins allosterically, which leads to rapid tau
clearance through the proteasome.84, 104 Moreover our lab has demonstrated that these
compounds do not damage microtubule dynamics while reducing abberant tau.104 This
scaffold has also been modified successfully to improve potency and blood brain barrier
permeability suggesting that this strategy could be useful in a clinical setting.104, 105 In
addition, members of the phenothiazine family, which contains compounds such as
methylene blue and azure C, also inhibit Hsp70 protein function, facilitate tau degradation
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via the proteasome and rescue memory deficits in tau transgenic mice.52, 106 Furthermore
there is evidence that these compounds also can induce autophagic clearance of tau,
highlighting the pleiotropic nature of this scaffold. Likewise inhibitors of another
chaperone, heat shock protein 90 (Hsp90), have anti-tau activity.107-109 Like Hsp70
inhibitors, these inhibitors also facilitate tau degradation via the proteasome. A number of
clinical trials have been conducted with Hsp90 inhibitors for other diseases, in particular
cancer, but the success with this approach has been modest due to pharmacological
challenges.110-112 Additionally, autophagic clearance has been shown to be beneficial in
attenuating tauopathies. Activating macroautophagy with rapamcyin was recently shown
to have efficacy in a transgenic model of tauopathy, potentially ushering in a new avenue
for tau expression reducing strategies aimed at autophagic pathways.113, 114 With this in
mind, the previous work showing that full-length monomeric tau is most efficiently cleared
via the proteasome, while cleaved, oligomeric and aggregated tau species are more
efficiently cleared via autophagy has elucidated the importance of developing drugs
targeting tau degradation.25, 42, 43, 46, 51, 115

1.5 Conclusion
Overall, there are a variety of experimental strategies to treat tauopathies. Most
have shown very adverse side effects and may not be as effective as current treatments.
However our lab’s strategy of regulating the protein quality control machinery allows us
to enhance or inhibit pathways shown to directly facilitate tau clearance or tau
accumulation. Furthermore this strategy may better allow for combinatorial treatment
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therapy which could be the next step in ameliorating the devastating pathology of
tauopathies.
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CHAPTER TWO:
SYNTHESIS, STEREOCHEMICAL ANALYSIS, AND DERIVATIZATION OF
MYRICANOL PROVIDE NEW PROBES THAT PROMOTE AUTOPHAGIC TAU
CLEARANCE
“Reproduced (or 'Reproduced in part') with permission from [Martin, M. D., Calcul, L., Smith, C., Jinwal, U.
K., Fontaine, S. N., Darling, A., Seeley, K., Wojtas, L., Narayan, M., Gestwicki, J. E., Smith, G. R., Reitz,
A. B., Baker, B. J., and Dickey, C. A. (2015) Synthesis, Stereochemical Analysis, and Derivatization of
Myricanol Provide New Probes That Promote Autophagic Tau Clearance, ACS Chem Biol.] Copyright
[2015] American Chemical Society."

2.1 Abstract
We previously discovered that one specific scalemic preparation of myricanol (1), a
constituent of Myrica cerifera (bayberry/southern wax myrtle) root bark could lower the
levels of the microtubule associated protein tau (MAPT). The significance is that tau
accumulates in a number of neurodegenerative diseases, the most common being
Alzheimer’s disease (AD). Herein a new synthetic route to prepare myricanol using a
suitable boronic acid pinacol ester intermediate is reported. An X-ray crystal structure of
the isolated myricanol (1) was obtained and showed a co-crystal consisting of (+)-aR,11Smyricanol (2) and (-)-aS,11R-myricanol (3) co-formers. Surprisingly, 3, obtained from
chiral separation from 1, reduced tau levels in both cultured cells and ex vivo brain slices
from a mouse model of tauopathy at reasonable mid to low µM concentration while 2 did
not. SILAC proteomics and cell assays revealed that 3 promoted tau degradation through
an autophagic mechanism, which was in contrast to other tau-reducing compounds
previously identified by our group. During the course of structure-activity relationship
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(SAR) development we prepared compound 13 by acid-catalyzed dehydration of 1. 13
had undergone an unexpected structural rearrangement through the isomyricanol
substitution pattern (e.g. 16) as verified by X-ray structural analysis. Compound 13
displayed robust tau-reducing activity and, importantly, its enantiomers reduced tau levels
similarly. Therefore, the semisynthetic analog 13 provides a foundation for further
development as an anti-tau activity agent without SAR being based on chirality.
2.2 Introduction
Aberrant accumulation of the microtubule associated protein tau is implicated in
~20 neurodegenerative disorders collectively termed tauopathies, including chronic
traumatic encephalopathy (CTE), Alzheimer’s disease (AD), frontal temporal dementia
linked to chromosome 17 (FTDP-17), Parkinson’s disease and Pick’s disease.1, 2 Some
of these diseases can be caused by mutations in the MAPT gene which result in amino
acid substitution in critical microtubule-interacting domains.3 Tauopathies may also result
from a cascade of pathological events, such as amyloid β aggregation, leading to
microtubule

destabilization

and

the

hyperphosphorylation

of

tau.4

Tau

hyperphosphorylation induces the formation of toxic tau-containing aggregates, resulting
in neuronal loss causing cognitive and motor deficits.5, 6
A number of strategies have been explored to treat tauopathies by targeting
mechanisms of tau biology directly. Kinase inhibitors have been used to reduce the
hyperphosphorylation of tau and subsequent formation of neurofibrillary tangles.
Inhibitors of known tau kinases such as glycogen synthase kinase 3β (GSK-3β), protein
kinase C (PKC), Fyn (Src Kinase), and others have shown decreases in tau pathology.7
This strategy has had mixed results in the clinic, but none of these inhibitors have been
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approved for practical use.8, 9 Immunotherapy is another strategy that is being extensively
investigated to treat tauopathies. Both active and passive immunotherapy approaches
can successfully remove pathological forms of tau in mouse models,7 but passive
immunization holds more promise in the clinic because of its higher selectivity for discreet
tau species and greater administrative control in the event of autoimmune reactions.
However, even this strategy has some safety concerns since phosphorylated tau species
are found in normal as well as AD brains.10 Nevertheless, clinical trials using passive
immunization with antibodies targeting tau are ongoing. Another strategy being explored
to treat tauopathies is inhibition of tau aggregation. A number of compounds have been
identified that can prevent paired helical filament (PHF) formation and cause PHF
disassembly.7 These compounds have also shown efficacy in mouse models of
tauopathy.11, 12 Replacing tau function with microtubule stabilizing compounds has also
shown efficacy in mouse models of tauopathy, and this strategy is currently in the early
stages of clinical development.13 But currently there are no approved treatments for the
tauopathies that target tau biology directly.7
The strategy that our lab has pursued over the past several years is distinct from
these other mechanisms in that we are trying to harness the protein quality control
machinery to promote tau degradation.14, 15 Molecules targeting heat shock proteins
(Hsp), ubiquitin ligase complexes, and deubiquitinating enzymes have been effective at
inducing proteasomal degradation of tau.16 For example, YM-01 and other members of
the rhodacyanine family potently inhibit the Hsp70 family of proteins, which concomitantly
leads to rapid tau clearance through the proteasome. This scaffold has also been
modified successfully to improve blood brain barrier permeability, suggesting that it could
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be useful therapeutically.17 Inhibitors of another chaperone, Hsp90, also have anti-tau
activity.18,
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Like Hsp70 inhibitors, these also facilitate tau degradation via the

proteasome. A number of clinical trials have been conducted with Hsp90 inhibitors for
other diseases, in particular cancer, but the success with this approach has been modest
due to pharmacological challenges.20-22 Members of the phenothiazine family, which
contains compounds such as methylene blue and azure C, also inhibit Hsp70 protein
function, facilitate tau degradation via the proteasome15 and rescue memory deficits in
tau transgenic mice;23 however there is evidence that these compounds also can induce
autophagic clearance of tau24. Recent work has shown that full-length monomeric tau is
most efficiently cleared via the proteasome,16,

25, 26

while cleaved, oligomeric and

aggregated tau species that are more closely tied to toxicity are more efficiently cleared
via autophagy.16 In fact, autophagic clearance has been shown to be most beneficial in
attenuating tauopathies. Activating autophagy with rapamycin was recently shown to
have efficacy in a transgenic model of tauopathy,27,
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potentially ushering in a new

avenue for tau expression reducing strategies aimed at autophagic pathways. For
example, molecules enhancing autophagosome biogenesis and inhibiting the mammalian
target of rapamycin (mTOR) both stimulate autophagic tau clearance.29 Thus, continuing
to identify novel small molecules that regulate tau metabolism through these protein
clearance pathways could allow us to better understand tau and proteostasis processes
as well as serve as a foundation for drug discovery efforts to treat tauopathies.
2.3 Results and Discussion
We previously showed that a scalemic isolate from myricanol (1) (86% ee (+)aR,11S-myricanol (2)) (Figure 2.1), a natural product derived from Myrica cerifera
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(bayberry/southern wax myrtle) root bark, lowered tau levels,30 but the relevance of the
stereochemistry and the mechanism through which this occurred remained unknown.31
One of the obstacles has been to obtain high yields of 2, and its enantiomer 3, via
synthetic means with completely characterized structure and purity.32-34 In addition to
improving the isolation of 1 from M. cerifera root bark,30 we here devised a novel synthetic
route for its production. The first reported synthesis of 1 relied upon the Ni(0)-mediated
coupling of a bis-iodide intermediate, in ~10% yield.32 The synthesis of 1 employed the
intramolecular cross coupling of an aryl boronic acid pinacol ester and an aryl iodide, as
the boronic acid pinacol ester functionality has been established as a useful partner in
macrocycle ring formation.35 Arylbromide 4 was converted to phenylpropionaldehyde 5
by palladium-mediated reductive coupling with allyl alcohol (Figure 2.1). Iodination of 5
proceeded primarily ortho to the methoxy group to give 6, in 76% yield.

4-(4-

Benzyloxy)butan-2-one 7 was converted to iodide 8, which then afforded boronic acid
pinacol ester 9. Intermediate 9 was treated with LDA followed by 6 to effect an aldol
condensation to give 10, after acid-mediated elimination to the α,β-unsaturated ketone,
in 39% overall yield. Intramolecular cyclization of 10 using a palladium catalyst gave
desired 11 in 22% yield. We also conducted experiments on related substrates bearing
two iodines without the boron acid pinacol ester using Ni(0) catalysts, which had also
been reported in the synthesis of the related natural product alnusone36 but found no
improvement over the ~10% yield reported earlier.32 The olefin was reduced and the
benzyl ethers of 11 were removed via hydrogenolysis, to give 12, reduction of which gave
1 (Figure 2.1).
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M. cerifera-derived 1 is a m,m-bridged diarylheptanoid consisting of the two
enantiomers 2 and 3, but 2 is in enantiomeric excess (~13:1 ratio).30 It could also possess
the two atropisomers, 2a and 3a (Figure 2.2A). To determine if synthetic 1 had a similar
enantiomer composition as purified 1, it was subjected to chiral separation by high
performance liquid chromatography (HPLC), resulting in two UV fraction peaks with
identical retention times as those observed for M. cerifera-derived 1 but at a 1:1 ratio
(Figure 2.2A and 2.2B). Crystal structures were obtained of the racemic purified 1 and the
purified enantiomer 2, allowing us to infer the structure of 3 (Figure 2.2C and 2.2D).
Analysis of the solid state structure shows the stereochemistry of the hydroxyl group on
the macrocyclic ring appears to direct two opposite atropisomer geometries relative to the
biphenyl rings, which are highly strained. The internal dihedral angle of the biphenyl is
31.5o, relative to the carbocyclic ring, whereas the external dihedral angle is 45.1o, which
means a 13.4o twist in the phenyl rings for the two rings combined. There is a 7membered ring hydrogen bond between the 5-OH and 4-OMe groups on the biphenyl
rings (2.6 Å between non-hydrogen atoms).37, 38
Previously, we showed that scalemic 1 isolated from M. cerifera had anti-tau
activity, while racemic 1 derived from another source did not.30 Therefore, we wanted to
determine whether synthetic 1 had efficacy against tau similar to M. cerifera-derived 1.
Indeed, using HEK293T cells stably overexpressing P301L tau (an FTD-causing mutation
prone to aggregation; HEK P301L) we confirmed that this newly synthesized 1 did in fact
lower tau levels (Figure B.1). Also in our previous work, we hypothesized that 2 was the
more abundant chiral isolate from 1 because it was the enantiomer in excess in 1 derived
from M. cerifera. However, this hypothesis was never confirmed because we did not
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isolate the enantiomers and analyze their anti-tau efficacy individually. Above, we
determined that both synthetic and M. cerifera-derived 1 only contained two of the four
possible isomers of 1; 2 and 3. But M. cerifera-derived 1 had a 14:1 ratio of 2 to 3, while
synthetic 1 had a 1:1 ratio (Figure 2.2). Therefore, we sought to determine if these
enantiomers each had anti-tau activity, or whether one of these was driving the majority
of the anti-tau efficacy of 1. HEK P301L cells were treated with either 2 or 3 over a 72 h
timecourse. Surprisingly, 30 µM of 3 decreased both phosphorylated and total tau levels
similarly after just 6 h treatment and levels were reduced by as much as 50% after 72 h.
In contrast, treatment with 2 at 30 µM did not reduce tau levels throughout the duration of
the experiment in this cell model (Figure 2.3A and 2.3B) despite previous work showing
anti-tau activity at higher concentrations.30 These surprising results indicated that the
chirality of 1 based on the asymmetric carbon C-11 of the macrocyclic ring and the
biphenyl atropisomerism are indeed essential for the anti-tau activity of 1, but not as
originally predicted based on the enantiomer excess inference.30 Instead, it is the minor
constituent of 1, 3, that is responsible for the majority of tau-lowering activity. Therefore,
any preparation of racemic 1 that possesses 2 and 3 together should have anti-tau
activity, but not all preparations of racemic 1 may lower tau levels because they could
possess a different isomer profile.
Our previous interpretation was based on an inference of two racemic mixtures of
naturally derived myricanol from two different sources; one from M. cerifera and the other
from another source not disclosed by Indofine Chemical, but was likely from Myrica rubra,
which is the typical source. The X-ray data from M. cerifera-derived myricanol that we
prepared here revealed the presence of only 2 isomers. However, no X-ray data was

28

collected on the racemic material obtained from Indofine Chemical, which possibly
possessed a distinct stereoisomer profile from our previous work.30 This could be due to
environmental or species differences between where the material used here and the
material used by Indofine Chemical were harvested and/or the methods used for
extracting the natural product. Either modification could result in epimerization of the
atropisomers. Also while in our previous work the chiral column HPLC revealed two peaks
in the racemic mixture from Indofine Chemical that appeared similar to the mixture we
isolated from M. cerifera ourselves, it is likely that the atropisomerism could not be
resolved with the column that we used. Another consideration is that the myricanol
purchased from Indofine Chemical may have lacked the same purity as the myricanol that
we purified. Any of these alterations could possibly explain the lack of activity of the 55:45
racemic preparation used in our previous work. Because of this unexpected result, we
were also concerned that 3 was possibly being metabolized in the cell, particularly given
its polyphenolic structure. Therefore we subjected lysates of cells treated with 3 for 1, 6,
and 24 hours to liquid chromatography mass spectrometry (LC-MS) analysis.
Interestingly, the amount of 3 found in cells increased over time likely due to cell
permeability and more importantly, there was no metabolite observed (Figure B.2). This
confirmed that 3 was indeed the active molecule.
We then compared the anti-tau activity of 3 to another well-established taureducing compound, YM-01.39 HEK P301L cells were treated with increasing
concentrations of 3 and YM-01 for 24 h (Figure 2.3C). YM-01 reduced the levels of tau at
lower concentrations than 3, but the difference was slight (IC 50 = 3 µM and 18 µM Figure
2.3D). We examined whether 24 h 3 treatment reduced the levels of other known tau
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mutations associated with disease. HEK293T cells were transfected with P301L, wildtype
(WT), G303V, V337M, R406W tau species containing all four microtubule binding
domains and no N-terminal insertions (4R0N) and were treated with the IC 50 of either YM01 (3 µM) or 3 (18 µM) for 24 h. While tau levels in most of these mutants were reduced
by either treatment, R406W tau was resistant to both compounds (Figure 2.3E and 2.3F).
This corroborates previous work showing that this particular tau mutant (R406W) is more
resistant to tau expression reducing agents, perhaps because of its more hydrophobic
structure.15
Next, we tested the anti-tau activity of 3 in a more physiologically relevant context,
using brain tissue from the rTg4510 mouse model, which overexpresses P301L tau.40
Acute ex-vivo brain slices were treated with YM-01 and 3 (Figure 2.3G) for 6 h.39, 41 These
slices can only survive for approximately 6-8 h. Therefore higher concentrations of
treatments are typically used to accelerate manifestation of activity. YM-01 significantly
reduced tau levels at 30 and 100 µM, as previously described.39 (-)-aS,11R-myricanol (3)
also significantly decreased tau levels in rTg4510 brain slices at higher concentrations
(100 and 150 µM) (Figure 2.3H). Thus, enantiomer 3 reduced tau levels in both cultured
cells and an ex vivo model of tauopathy.
We then sought to investigate the kinetics of tau clearance caused by 3 treatment.
To do this, we used a previously characterized cell model, the inducible iHEK WT tau cell
line.41 This cell model allows us to monitor the degradation of tau protein exclusively by
turning tau expression on and then off using tetracycline and monitoring tau levels after
transgene expression is suppressed. To assess how 3 affected tau degradation, iHEK
cells were induced to overexpress tau for 24 h and then tau expression was shut off by
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removal of the tetracycline. Cells were then treated with 3 over 24 h. After 6 and 24 h, 3
significantly enhanced the temporal clearance of tau protein compared to cells treated
with vehicle only (Figure 2.4A and 4B). This tau-specific chase experiment confirmed that
3 was in fact accelerating tau clearance, not regulating its production.
Using this same model, we investigated how 3 was impacting other well-known tau
epitopes. Tau expression was induced with tetracycline in iHEK WT tau cells for 24 h and
then tetracycline was removed to stop tau expression. Cells were then treated with 3 and
lysates harvested at indicated timepoints. After 1 h, 3 accelerated reductions of tau
phosphorylated at S396/S404 and T231 compared to cells treated with vehicle alone.
Levels of tau phosphorylated at S262 and S356 were unchanged compared to vehicle
treated cells, consistent with previous findings that this particular phospho-tau species is
resistant to tau-lowering agents15, 18 (Figure 2.4C and 4D). The clearance of both total tau
species (epitopes were αα 2-18, or 404-441) was accelerated by 3, but this occurred more
slowly than it did for pS396/S404 and T231 tau species. Thus, select phospho-tau species
are rapidly reduced by 3 treatment, while total tau levels are reduced, but with greater
latency.
We previously demonstrated that the anti-tau activity compound, YM-01, promoted
tau clearance through an ubiquitin-dependent proteasomal mechanism.39 This is
indicated by the accumulation of high molecular weight tau species following treatment
with YM-01 in HEK P301L cells (Figure 2.5A). However, we observed that treating these
same cells with 3 did not produce high molecular weight tau (Figure 2.5B). We also
showed previously that YM-01-mediated tau expression reduction was blocked when
cells were co-treated with a proteasomal inhibitor,39 but treating cells with the proteasomal
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inhibitor MG-132 had no impact on the anti-tau activity of 3 (Figure 2.5C and 5D),
suggesting that 3 was clearing tau through an alternative non-proteasomal mechanism.
We then turned to an unbiased approach to identify a possible mechanism that
was triggered by 3 to facilitate tau clearance. We used SILAC proteomic analysis on
lysates of the neuronal cell line (M17) treated with or without 3 to help elucidate its
possible mechanism of action. These experiments were performed in triplicate and data
was analyzed using the ingenuity pathway analysis (IPA) software. Any peptides
represented in only one of these triplicates were excluded from the analysis. To identify
which other compound(s) 3 most closely represented we turned to the top upstream
regulator prediction feature of the IPA software. Based on our SILAC proteomic results,
this feature allowed us to predict those compounds or proteins that activated or inhibited
similar pathways to those modulated by 3. Interestingly, the pathways activated by 3
treatment were the same as those activated by the compound sirolimus/rapamycin (Table
B.3). Rapamycin is a known autophagy activator and has previously been implicated as
a possible treatment for tauopathy.42, 43 Based on this insight, HEK P301L tau cells were
co-treated with the autophagy inhibitor, 3-methyladenine (3-MA) and 3. In the absence of
3-MA, 3 reduced tau levels as expected; however, when 3-MA was present, 3 activity
against tau was abrogated (Figure 2.6A and 6B). Compound 3 also induced LC3β in the
iHEK cell model (Figure 2.6C), a protein known to be elevated when autophagy is
activated.44, 45 These findings provided further evidence that part of the tau expression
reducing activity of 3 was due to activation of autophagy.
While 3 most closely resembled activated rapamycin signaling, there were other
pathways that were predicted to be somewhat impacted by 3 treatment, albeit to a lesser
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extent. Some of these pathways could be contributing to the effects of 3 on tau biology.
For example, 3 was shown to regulate a variety of translational proteins from the EIF2,
EIF4/p70S6K, and mTOR pathways (Table B.4). While our data from Figure 2.4 suggests
that impaired translation of tau is not a major contributor to the tau-lowering activity of 3,
it could be having some effect. In fact, we have previously shown that tau itself can alter
the EIF2 pathway,46 further suggesting a link between this mechanism and tau. We also
noticed that discreet phospho-tau species were being rapidly reduced by 3 (Figure 2.4C).
The pS396/S404 and pT231 epitopes most affected by 3 (Figure 2.4C) were those
typically phosphorylated by known serine/threonine tau kinases such as glycogen
synthase kinase 3β (GSK3β), Casein kinase 2 (CK2) and mitogen activated protein
kinase 1 (MAPK1/ERK2), as well as members of the protein kinase A family. While the
levels of GSK3β itself were not directly influenced by 3 according to the proteomic data,
an upstream kinase capable of modifying GSK3β signaling was; MAPK1/ERK247 (Table
B.5). In addition, both CK2 and a member of the PKA family were also reduced by 3
treatment (Table B.6). This could represent another mechanism through which 3 is
regulating tau biology; by decreasing levels of tau kinases. Overall, while our data
suggests that activation of autophagy is the major activity of 3 that promotes tau
clearance, our proteomic data provides additional details about other mechanisms
through which 3 could modify tau biology.
We then heated 1 in the presence of pTsOH for 24 h to try to eliminate the active
stereocenters and reduce the OH group at C11. The major product was the cyclized
tetralin derivative 13, in 45% yield (Figure 2.7A). We were surprised by the observation
of this derivative because rather than having the expected m,m-bridged substitution

33

(compound 14) pattern the molecule had rearranged to an o,m-bridge as determined by
X-ray crystallography (Figure 2.7B), likely because of the relief of ring strain in 1. The Xray crystal analysis of B showed the enantiomers of 13 as aR,10R and aS,10S but after
chiral HPLC no assignment was determined for (+)-13 and (-)-13. Myricanone (12) has
been reported to rearrange to 15 upon treatment with lewis acid boron trifluroride (BF 3 ),48
so we repeated this reaction. Reduction of 15 using sodium borohydride gave 16, which
is reported for the first time (Figure 2.7A). Interestingly, while compounds 12, 15, and 16
were inactive against tau (not shown), compound 13 maintained anti-tau activity that was
similar to 3, despite the rearrangement, alteration of the macrocycle ring and reduction of
the hydroxyl group at C11 (Figure 2.8A and 8B). This was important because it suggested
that the exposed hydroxyl moieties on the biphenyl motif were not causing tau
degradation through a pan-assay interference phenomenon.49 The enantiomers of 13
were separated and collected individually by chiral HPLC to evaluate whether the
chiralities (C10 and 1, 19-biphenyl) of 13 were as important for activity as those (C11,
1,2-biphenyl) for 3 were. Both (+)-13 ([α]20 D = +93.6 (c= 0.08, chloroform)) and (-)-13
([α]20 D = -100 (c= 0.09, chloroform) had similar activity against tau (Figure 2.8C),
suggesting that this molecule maintains anti-tau activity independent of chirality.
In conclusion, we have developed a new synthetic route for the production of 1.
The enantiomer 3 reduced tau levels in several models of tauopathy. This molecule
promoted tau clearance by activating autophagy, but SILAC proteomic analysis
suggested that other pathways may also be engaged to alter tau production and
phosphorylation. We also produced 13, a derivative of 1, and both (+) and (-) enantiomers
of 13 maintained tau expression reducing efficacy. We attributed this to several unique
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structural features that emerged during the preparation of 13. This work represents a
major step forward in understanding the stereochemistry and biochemistry of this scaffold,
and perhaps defines 3 and 13 as early stage anti-tau therapeutics and tools for
investigating autophagy.

Figure 2.1. Synthesis of 1.
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Figure 2.2. (continued on next page) Enantiomers of 1. a) Chemical structure of 1
comprised of the two enantiomers 2 and 3, and possible atropisomers, 2a and 3a. b)
Chiral HPLC traces of M. cerifera-derived myricanol, synthetic myricanol and M. ceriferaderived myricanol/ synthetic myricanol (1:1) reveal 86%, 2% and 42% ee, respectively. c)
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The single molecule of 2 shown is a part of a large asymmetric unit containing four
molecules of 2; d) the structure represented as a co-crystal consisted of two enantiomers
2 and 3 related by inversion center; Thermal displacement ellipsoids are drawn at 50%
probability level. Coloring scheme – red (O), gray (C) and white (H).
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Figure 2.3. (continued on next page) (-)-aS,11R-myricanol (3) is the enantiomer
responsible for anti-tau activity.

a) Representative western blot of lysates from

HEK293T cells stably overexpressing P301L tau (HEK P301L tau) treated with 2 or 3 for
indicated time points. b), Quantification of pTau (S396/404) and total tau (H150) levels
from cells treated with indicated compound and harvested at indicated timepoints over 72
h. c) Representative western blot of HEK P301L cells treated with indicated
concentrations of each compound for 24 h. d) Half maximal inhibitory values (IC 50 ) were
approximately 1.8 µM for YM-01 and 18.56 µM for 3. e) HEK293T cells were transiently
transfected with disease causing tau mutants and treated with IC 50 of each compound for
24 h. f) Schematic showing location of each mutation in the tau protein. g) Representative
western blot of lysates from acute brain slices from 4 month old rTg4510 transgenic mice
treated with indicated concentrations of YM-01 or 3 for 6 h. h) Quantification of tau levels
from g). Data are average ± standard error of the mean (SEM), n=3. Anti-tau activity of ()-aS,11R-myricanol was observed in >10 individual experiments.
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Figure 2.4. (-)-aS,11R-myricanol (3) significantly accelerates tau clearance and
selectively reduces distinct tau species. a) Representative western blot of tau levels
in tet-inducible HEK293 cells stably overexpressing WT 4R0N Tau (iHEK) treated with 3
(18 µM) for indicated timepoints and harvested 24 h post tetracycline removal. b)
Quantification of tau levels from a). Data are average ± standard error of the mean (SEM),
n=3. c) Representative western blot of tau levels in iHEK cells. Expression of WT Tau
was induced for 24 h with tetracycline (1 mg mL-1). Tetracycline was removed and cells
were all treated with 3 at the same time. Lysates were harvested at indicated timepoints
and analyzed by western blot for levels of indicated tau species. d) Quantification of
levels of each tau species in panel c). Data are average ± SEM, n=3.
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Figure 2.6. (-)-aS,11R-myricanol (3) clears tau via autophagy. a) Representative
western βlot of lysates from HEK P301L tau cells co-treated with 3 and the autophagy
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timepoints and analyzed by western blot for levels of LC3β. Densitometric values are
average ± SEM.
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B

Figure 2.7. Synthesis of 16, and a cyclized tetralin derivative thereof, 13. a) The
acid mediated dehydration of 1 produced cyclized tetralin 13 as the major product, in
which a rearrangement occurred. Compound 15 was prepared as described and reduced
to 16. b) The structure of 13 represented as a co-crystal consisted of two enantiomers
related by inversion center. Thermal displacement ellipsoids are drawn at 50% propability
level. Coloring scheme – red (O), gray (C) and white (H).
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Figure 2.8. Tau levels are decreased by 16-like tetralin derivative 13. a)
Representative western blot analysis of HeLa cells stably expressing 4R0N tau and
treated with compound 13 at indicated concentrations for 24 h. b) Representative western
blot analysis of HeLa tau cells and treated with compound 13 at 50 µM for indicated
timepoints. c) Representative western blot analysis of HeLa tau cells treated with either
(+)-13 or (-)-13 at indicated concentrations for 24 h.
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2.4 Materials and Methods
2.4.1 Methods
All chemicals and anhydrous solvents were purchased from commercially
available sources and used without additional purification. General solvents and reagents
were purchased from Fisher Scientific. HRMS was performed on JMS-T100LC AccuTOF
Reflectron Time-of-Flight Mass Spectrometer with ESI source, MS-50010BU TOFMS
Base unit; Resolution: 6,000 (FWHM), 5 ppm accuracy of mass value; and Agilent 7980
Gas Chromatography Quadrupole time of Flight Mass Spectrometer 7200 series with EI
source. 1H NMR spectra were obtained on a Varian Mercury 300-MHz NMR and Varian
500-MHz NMR DD cryoprobe. Chemical shifts are reported in parts per million (ppm, δ)
using various solvents as internal standards (CDCl 3 , δ 7.26; DMSO-d 6 , δ 2.50). 1H-NMR
splitting patterns were designated as singlet (s), doublet (d), triplet (t), or quartet (q).
Splitting patterns that could not be interpreted or easily visualized are recorded as
multiplet (m) or broad (br). Coupling constants were reported in hertz (Hz). Purity (%)
and mass spectral data were determined with a Waters Alliance 2695 HPLC/MS (Waters
Symmetry C18, 4.6 x 75 mm, 3.5 µm) equipped with a 2996 diode array detector from
210–400 nm; the solvent system is 5-95% acetonitrile in water with 0.1% TFA over 9 min
using a linear gradient. The chiral separation was performed with a Shimadzu 10AT HPLC
(Phenomenex Lux Cellulose-1, 10 x 250 mm, 5 µm) equipped with a SPD-10Av detector
at 254 nm; isocratic solvent system 1 of 5% isopropanol in hexane and isocratic solvent
system 2 of 3% isopropanol in hexane at a flow rate of 5 mL min-1 and retention times are
in minutes.
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2.4.2 Reagents
YM-01 was provided by J. Gestwicki. MG-132 was obtained from AG Scientific and
3-MA was obtained from Sigma Aldrich. 3-MA was solubilized in water to 0.2 M. All other
compounds were all solubilized in DMSO (Sigma Aldrich) to 30 mM. Lipofectamine 2000
from Invitrogen was used for all transfections.

2.4.3 Cell Culture
HEK293T (ATCC) cells stably expressing P301L 4R0N tau, BE(2)-M17 (ATCC)
cells and HEK293T cells were maintained in DMEM plus 10% FBS (Life Technologies),
1% Penicilin Streptomycin (Invitrogen), and 1% Glutamax (complete media; Thermo
Scientific). HEK293T cells stably overexpressing tetracycline regulatable WT Tau 4R0N
cells were maintained under Zeocin and Blasticidin S HCl (Invitrogen) selection in
complete DMEM. HeLa (ATCC) cells stably expressing V5-tagged 4R0N tau15 were
maintained under G418 selection in Opti-Mem plus 10% FBS (complete media;
Invitrogen) as previously described.15 Transfections were performed following Invitrogen
Plasmid DNA Transfection protocol using Opti-MEM. All cells were treated as indicated
and were harvested as previously described.15 Cells were washed twice in ice-cold PBS
then scraped in cold MPER (Fisher Scientific) containing protease and phosphatase
inhibitors (PIC III, Calbiochem, PI2 and PI3, Sigma, PMSF). Samples were allowed to
incubate on ice, vortexed, then centrifuged at 10,000 rpm for 5 min at 4°C to clear debris.

2.4.4 Ex Vivo Slice Cultures
All procedures involving experimentation on animal subjects were done in accord
with the guidelines set forth by the Institutional Animal Care and Use Committee of the
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University of South Florida. Male 4 month old rTG4510 slice cultures were treated and
maintained as previously described.30

2.4.5 Western blotting
After normalization of protein concentration by bicinchoninic acid (BCA)
(ThermoFisher), samples were run on 10% SDS-PAGE gels, transferred to PVDF
(Immobilon, EMD Millipore). Membranes were blocked for 1h in 7% nonfat dry milk in
TBS-T before probing with anti-tau antibodies H150 (Santa Cruz Biotechnology), and
pT231 (Anaspec). Anti-actin and anti-GAPDH were purchased from Sigma Aldrich and
Biodesign. All antibodies were used at a dilution of 1:1,000. Anti-S396/S404
phosphorylated tau antibody (pS396/404) was used at a dilution of 1:500 (provided by P.
Davies). Primary antibodies were decteced by the species appropriate secondary
antibodies (Southern Biotech). Antibodies were detected by ECL (ThermoFisher).

2.4.6 Densitometry (Quant)
All values are shown as percent vehicle following actin normalization ± standard
error and mean. Scion Image software was used to calculate densitometry of all western
blots.

2.4.7 SILAC/Proteomic analysis
M17 neuroblastoma cells were labeled for quantitation using SILAC media
supplemented with 10% dialyzed FBS, pen/strep, and L-lysine or 13C 6 -L-Lysine 2HCl for
M17 neuroblastoma cells (Thermo Scientific). Cells were maintained in T25 flasks and
subsequent procedure was followed as described in M17 neuroblastoma cells were
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labeled for quantitation using SILAC media supplemented with 10% dialyzed FBS,
pen/strep, and L-lysine or

13

C 6 -L-Lysine 2HCl for M17 neuroblastoma cells (Thermo

Scientific). Cells were maintained in T25 flasks and subsequent procedure was followed
as previously described.50 SILAC-fed neuronal M17 cells were treated with 3 or vehicle
for 72 h. Quantification was done using the Ingenuity Pathway Analysis software. The
experiment was performed in triplicate. Proteins without peptide representation in at least
two of the triplicates were excluded from the analysis.

2.4.8 Statistics
Statistical analyses were performed by one-way ANOVA tests or Student’s t-tests.
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CHAPTER THREE:
INHIBITION OF BOTH HSP70 ACTIVITY AND TAU AGGREGATION IN VITRO BEST
PREDICTS TAU LOWERING ACTIVITY OF SMALL MOLECULES
“Reproduced (or 'Reproduced in part') with permission from [Martin, M. D., Baker, J. D., Suntharalingam,
A., Nordhues, B. A., Shelton, L. B., Zheng, D., Sabbagh, J. J., Haystead, T. A., Gestwicki, J. E., and Dickey,
C. A. (2016) Inhibition of Both Hsp70 Activity and Tau Aggregation In Vitro Best Predicts Tau Lowering
Activity of Small Molecules, ACS Chem Biol.] Copyright [2016] American Chemical Society."

3.1 Abstract
The phenothiazine, rhodacyanine, and flavonol scaffolds with inhibitory activity
against the heat shock protein 70 (Hsp70) family of chaperones have been found to
enhance the degradation of the microtubule associated protein tau in cells, neurons and
brain tissue. This is important because tau accumulation is linked to neurodegenerative
diseases including Alzheimer’s disease (AD) and chronic traumatic encephalopathy
(CTE). Here we expanded upon this study to investigate the anti-tau efficacy of additional
scaffolds with Hsp70 inhibitory activity. Five of the nine scaffolds tested lowered tau
levels, with the rhodacyanine and phenothiazine scaffolds exhibiting the highest potency
as previously described. Because phenothiazines also inhibit tau aggregation in vitro, we
suspected that this activity might be a more accurate predictor of anti-tau activity.
Interestingly, the rhodacyanines did inhibit in vitro tau aggregation to a similar degree as
phenothiazines, correlating well with tau expression reducing efficacy in cells and ex vivo
slices. Moreover, other Hsp70 inhibitor scaffolds with weaker tau expression reducing
activity in cells inhibited tau aggregation in vitro, albeit at lower potencies. When we tested
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six well-characterized tau aggregation inhibitors, we determined that this mechanism of
action was not a better predictor of tau expression reduction than Hsp70 inhibition.
Instead we found that compounds possessing both activities were the most effective at
promoting tau clearance. Moreover, cytotoxicity and PAINS activity are critical factors that
can lead to false-positive lead identification. Strategies designed around these principles
will likely yield more efficacious tau expression reducing compounds.
3.2 Introduction
Aggregation and accumulation of the microtubule associated protein tau is a
common feature of several neurodegenerative diseases, referred to as tauopathies,
which include chronic traumatic encephalopathy (CTE), Alzheimer’s disease (AD), frontal
temporal dementia linked to chromosome 17 (FTDP-17), Parkinson’s disease and Pick’s
disease.1, 2 A plethora of therapeutic strategies have been employed to attempt to prevent
aberrant tau accumulation and toxicity, including kinase inhibitors, humanized antibodies,
aggregation inhibitors, microtubule stabilizing compounds and small molecules targeting
degradation machinery.3-11 Some of our original work sought to identify molecules that
could simply facilitate tau clearance, regardless of any particular known mechanism of
action. 12, 13 While many of the compounds identified were largely cytotoxic, leading to a
perceived reduction in tau, through these studies, we were able to identify chaperone
modulators as one family of compounds capable of anti-tau activity independent of this
toxicity.12 In particular, inhibitors of the Hsp70 chaperone family are highly effective at
lowering tau.8, 14 When the activity of these molecular chaperones is pharmacologically
or even genetically inhibited, tau can be degraded.15-18 Recently a number of other small
molecules with anti-Hsp70 activity have been described. Some of these Hsp70 inhibitor
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scaffolds mimic ATP and act as a competitive inhibitor in the ATP pocket, while others
are thought to act allosterically, blocking cofactor or substrate interactions.19, 20,
26, 27, 28

8, 9, 21-25,

But, the activity of these compounds against tau remains unknown.
In addition, several of the published molecules with Hsp70 inhibitory activity are

known to have other mechanisms of action, perhaps as a result of their prevalence in
existing chemical libraries and their possible pan-assay interference properties. In
particular, the phenothiazine, methylene blue (MB), which has been identified as a potent
Hsp70 inhibitor and an autophagy inducer, also possesses other activities due to its redox
potential. 22, 45 In fact, one such activity is inhibition of tau aggregation in vitro, an activity
that was discovered two decades ago.34 MB is thought to inhibit tau aggregation by
covalent modification of tau via cysteine oxidation.29, 30 Because tau has two naturally
occurring cysteine residues located in the microtubule binding domain, it can form
intermolecular disulfide bonds with neighboring tau molecules leading to aggregate
formation.31-33 MB creates disulfide bonds within the same tau molecule disrupting
fibrillization.29 Since MB has been shown to reduce tau levels in multiple tauopathy
models34-36 , which has precipitated clinical trials of related derivatives for AD and FTD, it
is difficult to know which activity, Hsp70 inhibition or aggregation inhibition, is most
responsible for its ability to facilitate tau clearance.34, 37, 38 In this regard, several other
studies have identified tau aggregation inhibitors, but the ability of these compounds to
promote tau clearance has not been presented for most of these. For example, the olive
oil phenols, aminothienopyridazine (ATPZ), rhodanines and anthraquinones all prevent
tau aggregation in vitro, yet it is not known if this activity is sufficient to facilitate tau
reductions in living cells. 39 6, 40-42
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Based on this information, we sought to evaluate if Hsp70 or aggregation inhibition
was a better predictor of tau expression reduction in cells. With this in mind, we collected
a number of known Hsp70 and aggregation inhibitors, and assessed their activities
against tau. Interestingly, neither in vitro activity alone was a strong predictor of anti-tau
activity in cells. Rather, only those molecules possessing potent activity against both
Hsp70 ATPase function and tau aggregation in vitro, facilitated tau clearance independent
of toxicity. Here, we describe the implications of these findings for tau-based drug
discovery efforts, and how this information could be used to improve the success rate for
translation of leads identified from in vitro assays into pre-clinical and clinical studies.

3.3 Results and Discussion
Based on our previous reports that methylene blue and the compound YM-01, a
derivative of MKT-077 from the rhodacyanine scaffold, both inhibited Hsp70 activity and
lowered tau levels in a cell tauopathy model8, 14, we hypothesized that it was in fact the
Hsp70 ATPase inhibition that was the best predictor of anti-tau activity in cells. To
investigate this, we examined the tau expression reducing capability of several other
published Hsp70 inhibitors, listed in Table 3.1.

Compounds for each scaffold were

assessed for tau-lowering efficacy. Human embryonic kidney (HEK293T) cells, transiently
overexpressing WT4R0N tau were treated with increasing concentrations of each
compound for 24 h. Interestingly, vast differences in tau-lowering activity were found
among the molecules. Compounds from the piperidine-3-carboxamide and the adenosine
analog scaffolds surprisingly increased tau levels. In contrast, the rhodacyanine and
phenothiazine compounds still potently reduced tau levels at all concentrations. However
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the dihydropyrimidine, phenoxy-N-arylacetamide, sulfonamide, and flavonol scaffolds
only lowered tau levels at the highest concentration tested, 30 µM (Figure 3.1A,B). Similar
trends were observed for these compounds in a stably transfected HEK P301L tau cell
line (Figure C.1). These data indicate that allosteric Hsp70 inhibitors might be more likely
to possess tau-lowering activity than those that directly target the ATP binding site.
Perhaps more importantly, because all of these compounds target the same mechanism
of action, we concluded that Hsp70 inhibition alone was insufficient to predict anti-tau
activity by greater than ~60% predictive accuracy.
Because methylene blue also inhibits in vitro tau aggregation, we then speculated
that tau expression reducing efficacy could be better predicted by in vitro anti-tau
aggregation activity. To test this, we evaluated the anti-tau activity of several
commercially available tau aggregation inhibitor scaffolds including carbocyanine,
aminothienopyridazine (ATPZ), polyphenols, anthraquinone, and rhodanine (Table 3.2).
Surprisingly, only two of these compounds lowered tau levels in our HEK293T tauopathy
cell model; carbocyanine and anthraquinone (Figure 3.2A,B). However, the activity of
carbocyanine coincided with very high cytotoxicity as suggested by the reduced actin
levels. Thus, only the anthraquinone at 30µM effectively lowered tau levels, possibly
suggesting another unknown mechanism for this particular molecule. In this way, tau
aggregation inhibition alone is an even worse predictor of anti-tau activity than Hsp70
inhibition.
Since neither of these mechanisms alone was sufficient to predict anti-tau activity,
we speculated that perhaps compounds with dual activities might be more likely to
facilitate tau clearance in cells. This was largely based on the known pleiotropy of
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methylene blue. Therefore, we investigated whether those Hsp70 inhibitors capable of
lowering tau might also have activity against its aggregation in vitro. To test this, 10 µM
4R0N human recombinant tau was incubated with each compound at increasing
concentrations for 1 h at 37°C. After one hour incubation, 10 µM heparin was added to
the tau compound mixture and incubated for a further 24 h at 37°C prior to reading the
fluorescent intensity of each mixture. Increases in fluorescence intensity indicate
enhanced tau amyloid formation. Interestingly, we found that compounds from the
rhodacyanine and phenothiazine scaffolds had high anti-tau aggregation potency with
IC 50 s of .813 µM and 1.35 µM, respectively. Less potent tau-lowering scaffolds such as
dihydropyrimidine, phenoxy-N-arylacetamide, and flavonols had higher IC 50 s (22.7, 6.93,
and 9.74 µM, respectively). In contrast the compounds that increased tau levels in our
cell model, piperidine-3-carboxamide and adenosine analog, also increased tau
aggregation levels in vitro (Figure 3.3A). To confirm in vitro anti-tau aggregation activity
of the tau-lowering compounds, non-denaturing gel electrophoresis was performed. The
most potent tau-lowering scaffold compounds, rhodacyanine and phenothiazine, also
most potently reduced high molecular weight tau compared to other compounds and the
tau alone control; however all compounds with anti-tau activity also reduced high
molecular weight tau aggregation (Figure 3.3B,C). Since MB is known to alter cysteine
oxidation in tau, a mechanism that can contribute to its anti-aggregation activity, 29 we
suspected that the rhodacyanines may be acting through a similar mechanism. However,
when we tested for the production of hydrogen peroxide following incubation of
recombinant tau with 30 µM rhodacyanine, no significant differences were observed
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(Figure C.2). Thus, those compounds capable of inhibiting both Hsp70 activity and tau
aggregation in vitro predicted tau lowering activity by ~80% predictive accuracy.
One interesting outcome from these analyses was the discovery that the antiaggregant compound ATPZ did not lead to tau expression reduction, despite it having the
same exact anti-aggregation mechanism as MB; alteration of cysteine oxidation.29 We
speculated that the lack of tau-lowering activity may be due to ATPZ’s inability to inhibit
Hsp70 ATPase activity. Therefore we examined the Hsp70 inhibitory activity of not only
ATPZ but of each aggregation inhibitor. Recombinant human Hsp70 and DnaJA2 were
incubated with increasing concentrations of each compound for 30 min, followed by
addition of ATP and subsequent 3 h incubation. We measured absorbance by malachite
green assay as previously described21. None of the aggregation inhibitor scaffolds that
failed to lowered tau inhibited Hsp70 ATPase activity, with the exception of the rhodanine
scaffold (Figure 3.4), a known PAINS molecule that can be effective in any assay due to
Michael reactions.43, 44
One final variable that we needed to consider for these results was the role of
cytotoxicity in perceived tau reductions. We previously found that compounds with high
cytotoxicity caused tau expression reduction, perhaps due to microtubule breakdown.12,
45, 46

We speculated this to be the case for the carbocyanine and possibly some of the

other outliers in these studies. Therefore, we tested the cytotoxicity of all compounds at
increasing concentrations using a lactate dehydrogenase (LDH) assay. The data revealed
that the both the sulfonamide compound and the carbocyanine had high toxicity relative
to the other compounds, explaining why they were leading to perceived tau reductions
(Figure 3.5). Thus, compounds with activity against both Hsp70 activity and tau
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aggregation in vitro can predict anti-tau activity at greater than 90% predictive accuracy
when both cytotoxicity and PAINS classification are accounted for.
Overall neither Hsp70 inhibition nor anti-tau aggregation activity alone is sufficient
to predict tau lowering in an in vitro model by more than 50%, although Hsp70 inhibition
appears to be a better predictor than aggregation inhibition. But compounds that possess
both activities, exemplified by the phenothiazines and rhodacyanines, are highly likely to
promote tau clearance in cells and neurons (Figure C.3). Importantly, the higher the
potency of Hsp70 inhibitors against tau aggregation, the more potent the tau-lowering,
suggesting a synergy of these two mechanisms. Perhaps compounds with both activities
can keep tau in a unique conformation that better facilitates its clearance. While there are
certainly other mechanisms of tau clearance and molecules with distinct activities that
could lead to tau degradation, these findings suggest that a drug screening campaign
based first on Hsp70 inhibition with follow up assays examining tau aggregation,
cytotoxicity and pan-assay interference, will likely yield less false-positive leads with
regard to cellular activity against tau.47 This concept of polypharmacy has been gaining
ground over the past few years. While target specificity is still a major goal of modern
drug discovery, it is clear that compounds with multiple targets can have clinical benefit
despite their pleiotropy.48-50 In particular, compounds that target multiple relevant
mechanisms for single diseases may be more effective than compounds with single
mechanisms of action.48, 49
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Table 3.1. Summary of published Hsp70 inhibitors.
Scaffold

Rhodacyanine

Nomenclature
(Compound Name)

Compound Structure

3-benzyl-2-((Z)-((E)-5-(6-chloro-3methylbenzo[d]thiazol-2(3H)ylidene)-3-ethyl-4-oxothiazolidin-2ylidene)methyl)thiazol-3-ium
chloride
(JG-98)

N

S

N

Hsp70/Dna
J
Inhibitory
Activity
Reported
(Li et al.,
2013;
Rousaki et
al., 2011)

S

N
S

Cl

O

Dihydropyrimidi
ne

4-[1,1′-Biphenyl]-4-yl-3,4-dihydro6-methyl-2-oxo-5[(phenylmethoxy)carbonyl]-1(2H)pyrimidinehexanoic acid
(116-9E)

(Chang et
al., 2008;
Wisen et
al., 2010)

H
N

O
O
N

Hsp70
Family
member
targeted

Anti-Tau
Activity
Reported

HSPA8
(Hsc70);
HSPA9
(Mortalin
);
HSPA1
(Hsp72);
SSA1
(Hsp70
yeast)
DnaK
(Hsp70
Bacterial
)
DnaK
(Hsp70
Bacterial
)

(Fontaine
et al.,
2015;
Rousaki
et al.,
2011)

HSPA1
(Hsp72)

(Jinwal et
al., 2009;
Wischik,
Edwards,
Lai, Roth,
&
Harringto
n, 1996)

Unknown

O

HO
O

Phenothiazine

3,7bis(Dimethylamino)phenazathioniu
m chloride
(Methylene Blue)

Cl
+

N

S

N
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N

(Chang et
al., 2008;
Jinwal et
al., 2009;
Miyata et
al., 2012)

Table 3.1 (Continued)
Piperidine-3(S)-N-(1-propyl-1H-benzimidazolCarboxamide
2-yl)-1-(2-pyrazinyl)piperidine-3carboxamide
(HS72)

(Howe et
al., 2014)

HSPA1
(Hsp72)

Unknown

(Williamson
et al., 2009)

HSPA8
(Hsc70);
HSPA1
(Hsp72)

Unknown

N

O

N
N
H
N

N
N

Adenosine
Analog

5′-O-[(4-Cyanophenyl)methyl]-8[[(3,4dichlorophenyl)methyl]amino]adenosine
(VER-155008)

H 2N

N

Cl

N

HN
N

Cl

N

O

OH
O
HO

N
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Table 3.1 (Continued)
Phenoxy-Nbutyl 3-[2-(2,4Arylacetamide
dichlorophenoxy)acetamido]benzo
ate
(ALSB-2970)

O

O

O
O

(Cassel,
Ilyin,
McDonnell,
& Reitz,
2012)

targets
and
binds to
DNAJ

Unknown

(Leu,
Pimkina,
Frank,
Murphy, &
George,
2009)
(Chang et
al., 2008;
Chang et
al., 2011;
Jinwal et
al., 2009)

HSPA1
(Hsp72)
DnaK
(Hsp70
Bacterial
)
HSPA8
(Hsc70)
DnaK
(Hsp70
Bacterial
)

Unknown

N
H

Cl

Sulfonamide

O

2-Phenylethynesulfonamide
(PES)

S

NH2

O

Flavonol

3,3′,4′,5,5′,7-Hexahydroxyflavone
(Myricetin)

OH
OH

HO

O
OH

OH
OH
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O

(Jinwal et
al., 2009)

A

Rhodacyanine (µM) -

3 10 30

Dihydropyrimidine (µM) -

Tau
Actin
Phenothiazine (µM) -

Tau
Actin
3 10 30

Piperidine-3-Carboxamide(µM) -

Actin

3 10 30

Phenoxy-N-Arylacetamide (µM)
Tau
Actin

3 10 30

Flavonol (µM)
Tau
Actin

Tau
Actin
(µM) Tau
Actin

B
200
150

% tau levels

3 10 30

Tau
Actin

Tau

Adenosine Analog (µM) -

3 10 30

VEH

100

- 3 10 30

-

3 10 30

Rhodacyanine **
Dihydropyrimidine ***
Phenothiazine *
Piperidine-3-Carboxamide ***
Adenosine Analog
Phenoxy-N-Arylacetamide ***
Sulfonamide ***
Flavonol ***

50
0
-1

-2

0

2

1

log Concentration (µM)
Figure 3.1. Diverse Hsp70 inhibitor scaffolds have differing effects on tau levels.
(A) Representative western blot analysis of HEK293T cells transiently transfected
WT4R0N tau and treated with each Hsp70 inhibitor at indicated concentrations for 24 h.
(B) Quantification of tau levels in panel (A) as a percentage of vehicle treated ± standard
error of the mean (SEM), n=3. By linear regression analyses, *** indicates p<0.001, **
indicates p<0.01.
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Table 3.2. Summary of published tau aggregation inhibitor scaffolds.
Scaffold

Nomenclature
(Compound Name)

Compound Structure

Anti-Tau
Aggregatio
n Inhibitory
Activity
Reported
(Congdon et
al., 2009;
Duff, Kuret,
& Congdon,
2010)

Tau
Mutant
Targete
d

Intracellula
r Anti-Tau
Activity
Reported

Wild
Type

(Congdon
et al., 2009)

Carbocyanine

3,3′-Diethyl-9methylthiacarbocyanine
iodide
(C11)

Aminothienopyridazi
ne

5-amino-3-(4chlorophenyl)-Ncyclopropyl-4-oxo-3,4dihydrothieno[3,4d]pyridazine-1carboxamide
(ATPZ)

(Ballatore et
al., 2010;
Crowe et
al., 2009)

Wild
Type;
P301L;
K311D

Unknown

Polyphenol

(2S,3E,4S)-3-Ethylidene2-(β-Dglucopyranosyloxy)-3,4dihydro-5(methoxycarbonyl)-2Hpyran-4-acetic acid 2(3,4dihydroxyphenyl)ethyl
ester
(Oleuropein)

(Daccache
et al., 2011)

P301L

Unknown
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Table 3.2 (Continued)
Polyphenol

2-(3,4Dihydroxyphenyl)ethanol,
3,4-Dihydroxyphenethyl
alcohol
(Hydroxytyrosol)

(Daccache
et al., 2011)

P301L

Unknown

Anthraquinone

1,2,5,8-Tetrahydroxy9,10-anthraquinone,
1,2,5,8Tetrahydroxyanthraquino
ne
(Quinalizarin)

(Duff et al.,
2010;
Pickhardt et
al., 2005)

Wild
Type;
ΔK280

Unknown

Rhodanine

2-((Z)-5-((5-(3chlorophenyl)furan
-2-yl)methylene)-4-oxo-2thioxothiazolidin-3yl)ethanoic acid
(Compound 1)

(Bulic et al.,
2007; Bulic,
Pickhardt,
Mandelkow,
&
Mandelkow,
2010)

Wild
Type;
ΔK280

Unknown
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Figure 3.2. Diverse tau aggregation inhibitor scaffolds have differing effects on tau
levels. (A) Representative western blot analysis of HEK293T cells transiently transfected
WT4R0N tau and treated with each tau aggregation inhibitor at indicated concentrations
for 24 h. (B) Quantification of tau levels in panel (A) as a percentage of vehicle treated ±
standard error of the mean (SEM), n=3. By linear regression analyses, *** indicates
p<0.001, ** indicates p<0.01, * indicates p<.05.
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Figure 3.3. Diverse Hsp70 inhibitor scaffolds have differing effects on tau
aggregation in vitro. (A) anti-Hsp70 compounds; quantification of in vitro ThT assay
using recombinant P301L tau incubated with drug at increasing concentrations for one
hour prior to addition of 20 µM heparin which was then incubated for 24 h. Data are
average ± standard error of the mean (SEM), n=3. (B) Non-denaturing gel electrophoresis
of anti-aggregation ThT samples from (A). (C) Quantification of tau aggregate levels from
(B). Data are average ± standard error of the mean (SEM), n=3.
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Figure 3.4. Tau aggregation inhibitor scaffolds do not inhibit Hsp70 ATPase
activity. Hsp70 Quantification of ATPase activity using recombinant human Hsp70 and
DnaJA2 protein. Activities are a percentage of vehicle treated ± standard error of the
mean (SEM), n=3.
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Figure 3.5. Determination of LDH cytotoxicity of Hsp70 and Tau aggregation
inhibitors in HEK293T cells. HEK293T cells (10,000 cells per well) were plated in a 96well plate and incubated overnight at 37°C. After 24 h, increasing concentrations of
inhibitors were added to the culture media and incubated for 24 h at 37°C. LDH
cytotoxicity was measured using the Pierce LDH Cytotoxicity Assay Kit. Values are
relative to DMSO control.
3.4 Materials and Methods
3.4.1 Cell Culture
HEK293T cells were maintained in DMEM plus 10% FBS (Life Technologies), 1%
Penicilin Streptomycin (Invitrogen), and 1% Glutamax (complete media; Thermo
Scientific). Transfections were performed following the Invitrogen Plasmid DNA
Transfection protocol using Opti-MEM. All cells were treated as indicated and were
harvested as previously described.9 Cells were washed twice in ice-cold PBS, then
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scraped in cold mammalian protein extraction reagent (M-PER; Fisher Scientific)
containing PMSF, protease and phosphatase inhibitors. Samples were incubated on ice,
vortexed, then centrifuged at 10,000 rpm for 5 min at 4°C to clear debris. Assays were
run in triplicate and statistical significance was assessed by t-test.

3.4.2 Aggregation Kinetics (Thioflavin T) Assay and Immunoblot
Samples consisting of 10 µM purified human recombinant Tau P301L, 2 mM
diothiothreitol, indicated drug concentration, 10 µM heparin, and 10 µM thioflavin T in 100
mM sodium acetate buffer at pH 7.4 were prepared. 200 µL of indicated sample was
added to a black, sealed, clear-bottom 96 well plate (Corning costar 3603). Plates were
incubated at 37°C and fluorescence (440 emission, 490 excitation) was observed over a
24 h time course, with periodic readings using a BioTek Synergy H1 microplate reader.
Following ThT analyses, recombinant fibrils were analyzed by Native-PAGE (nondenaturing conditions), followed by immunoblotting for tau. Specifically, samples
incubated with 30µM of each compound were analyzed in this way.

3.4.3 Hydrogen Peroxide Assay
Hydrogen peroxide production was measured as previously described.

29

Briefly,

recombinant human P301L tau (10 µM) was incubated with 30 µM rhodacyanine or
equivalent vehicle (DMSO). Hydrogen peroxide production was measured using the
PeroXQuant assay (Pierce 23280) according to manufacturer instructions.
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3.4.4 Hsp70 ATPase Assay
Recombinant human Hsp70 and DnaJA2 were used in a malachite green assay. A master
mix of Hsp70:DnaJA2 at 1 µM prepared in assay buffer (0.017% Triton X-100, 100 mM
Tris–HCl, 20 mM KCl, and 6 mM MgCl2, pH 7.4). An aliquot (14 μL) of this mixture was
added into each well of a 96-well plate. To this solution, 1 μL of either compound (3, 10,
30, 100, or 200 μM) or DMSO was added and the plate was incubated for 30 min at 37
°C before adding 10 μL of 2.5 mM ATP to start the reaction. Thus, the final reaction
volume was 25 μL and the conditions were 1 μM Hsp70, 1 μM DnaJA2, 4% DMSO, 0.01%
Triton X-100, and 1 mM ATP. After 3 h incubation at 37 °C, 80 μL of malachite green
reagent was added into each well. Immediately after this step, 10 μL 34% sodium citrate
was used to stop the nonenzymatic hydrolysis of ATP. The samples were mixed
thoroughly and incubated at 37 °C for 15 min before measuring OD620 on a BioTek
Synergy H1 microplate reader as previously described.21

3.4.5 Lactate Dehydrogenase (LDH) Assay
LDH cytotoxicity was measured using the Pierce LDH Cytotoxicity Assay Kit. Values are
presented as the percent of LDH release compared to DMSO (Vehicle) treated cells.

3.4.6 Western Blotting
After normalization of protein concentration by bicinchoninic acid (BCA) (ThermoFisher),
samples were run on 10% SDS-PAGE gels (for non-denaturing gel electrophoresis
samples were run without β- mercaptoethanol on a 4-15% gradient PAGE gel) and
transferred to PVDF membranes (Immobilon, EMD Millipore). Membranes were blocked

72

for 1 h in 7% nonfat dry milk in TBS-T before being probed with antibodies directed against
total tau (H150; 1:1000; Santa Cruz Biotechnology), tau phosphorylated at S396/404
(PHF1; 1:500; provided by P. Davies), ß-actin (1:1000; Sigma-Aldrich), or GAPDH
(1:1000; Biodesign). Primary antibodies were detected by species appropriate secondary
antibodies (Southern Biotech) and chemiluminescence was detected by ECL
(ThermoFisher). Scion Image software was used to calculate densitometry of all western
blots. All values are shown as percent vehicle following actin normalization ± standard
error of the mean.
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CHAPTER FOUR:
FINAL PERSPECTIVES
In our study we demonstrated that small molecules targeting tau degradation
pathways are effective in enhancing tau turnover. We initially synthesized a natural
product from bayberry root bark, myricanol, and found it could reduce tau levels in multiple
models of tauopathy.1 We then discovered that one of its enantiomers, (+)-aR,11Smyricanol (3), was responsible for its anti-tau activity.2 Moreover we revealed the
mechanism of 3’s tau clearance to be the stimulation of macroautophagy.2 We lastly made
derivatives of myricanol that did not depend on stereochemistry in order have anti-tau
activity.2 This has given the field another small molecule besides rapamycin that can
increase autophagic processing through macroautophagy to degrade client proteins such
as tau.
In our next study we found that several known Hsp70 inhibitor scaffolds could
lower cellular tau levels. We also discovered that many of the known tau aggregation
inhibitor scaffolds unexpectedly did not lower tau levels. This then led us to investigate
which activity, Hsp70 inhibition or tau aggregation inhibition, was more predictive of antitau activity. Interestingly, we found that both activities together were required to lower tau
levels. We discovered this phenomenon from the active tau reducing Hsp70 inhibitors
having in vitro anti-tau aggregation activity and the ineffective tau aggregation inhibitors
not having anti-Hsp70 ATPase activity. There was even a positive correlation between
the tau lowering and anti-tau aggregation activity of each tau lowering Hsp70 inhibitor.
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This work serves to help improve the field’s screening strategies for tau expression
reducing compounds. In addition this provides more scaffolds that can be further
developed to treat tauopathies.
With this in mind one of the most successful clinical trial compounds to treat AD,
FTD and other tauopathies has been the phenothiazine compound, methylene blue or
LMTX®.3-5 As previously discussed in Chapters 1 and 3, MB can prevent tau aggregation,
inhibit Hsp70, and improve autophagic processing.6-10 All of these activities we
hypothesize can synergize together be an effective treatment. However this strategy has
not received more attention in the clinical setting due to lack of research showing the
synergistic effects of combining tau aggregation inhibitors with inhibitors that can enhance
proteasomal and/or autophagic degradation. Furthermore there have been a lack of
candidate compounds known to possess both activities.
While MB has been the most successful dual activity compound to date to treat
tauopathies, we have shown that the rhodacyanine scaffold could be further developed
and used clinically. We have demonstrated that the rhodacyanine scaffold is equally as
potent in lowering tau levels as the phenothiazine scaffold. In addition the rhodacyanine
scaffold not only prevents tau aggregation (Chapter 3) but also simultaneously promotes
tau clearance through proteasomal degradation.11 Moreover our lab has characterized
the structure-activity relationship (SAR) in these derivatives. We have identified several
regions of this scaffold that could be modified to improve potency, blood brain barrier
permeability or even bioavailability. These derivatives are shown in Table 4.1.
Overall our findings suggest a new therapeutic approach should be considered for
the treatment of tauopathies which is combination therapy. The use of dual acting
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compounds such as MB and JG-98 or simultaneous treatments with a tau aggregation
inhibitor and a tau degradation pathway stimulator will be most effective in preventing or
stopping the devastating pathology in many tauopathies.

Table 4.1. Structure-Activity Relationship of Rhodacyanine Derivatives. In HEK
tau cells, ↓ indicates ≤ 30% reduction in tau at 30µM, ↓↓ indicates >30 but ≤ 60% reduction
in tau 30µM, and ↓↓↓ indicates >60% but ≤ 90% reduction in tau at 30µM in cell culture.
Toxicity was determined by cell proliferation MTS assay in HEK cells. + or – indicates
>10% or <10% toxicity at 10µM in cell culture, respectively. No compounds showed
>30% toxicity up to 30µM. If cell survival was < 90% at 10µM, drug was considered toxic.
In slice cultures from mouse brain + or – indicates >30% or <30% reduction up to 100µM,
respectively.
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(cells)

Tau
Activity
(slices)

H
H
2-Cl
2-CF 3

ethyl
ethyl
ethyl
ethyl

methyl
H
benzyl
benzyl

13-pyridyl
13-pyridyl
13-thiazolyl
13-thiazolyl

↓↓
↓↓
↓↓↓
↓↓↓

+
+
+
+
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Toxicity
MTS
assay
(cells)
+
+

Table 4.1 (Continued)

2-CF 3

ethyl

methyl

13-pyridyl

↓↓

2-CF 3

methyl

13-pyridyl

↓

benzyl

13-thiazolyl

↓

2-CF 3

methyl
acetate
methyl
acetate
ethyl

methyl

13-thiazolyl

↓

2-CF 3

ethyl

ethyl

13-thiazolyl

↓

2-CF 3

ethyl

ethyl

13-pyridyl

↓↓

2-CF 3

ethyl

H

13-pyridyl

H

methyl
acetate
methyl
acetate
methyl
acetate
methyl
acetate
methyl
acetate
methyl
acetate
methyl
acetate
methyl
acetate
methyl
acetate
methyl
acetate
ethyl

H

13-pyridyl

H

13-thiazolyl

H

13-pyridyl

H

13-thiazolyl

H

13-pyridyl

H

13-pyridyl

H

15-pyridyl

H

15-pyridyl

H

13-pyridyl

H

13-pyridyl

H

15-pyridyl

H

13-pyridyl

2-Cl

methyl ester
propanoate
ethyl

H

13-thiazolyl

2-CF 3

ethyl

H

13-thiazolyl

3methyl
ester

ethyl

methyl

13-pyridyl

No
Change
No
Change
No
Change
No
Change
No
Change
No
Change
No
Change
No
Change
No
Change
No
Change
No
Change
No
Change
No
Change
No
Change
No
Change
↓

2-CF 3

H
2-CF 3
2-CF 3
2-F
3-F
2-F
3-F
4-F
1-F
2-CF 3
2-F
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Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
Not
tested
+

-

Table 4.1 (Continued)

13-pyridyl

↓↓

+

-

↓

+

-

methyl
methyl

13-pyridyl,
13-pyrazyl
13-pyridyl
13-pyridyl

↓↓
↓

+
+

-

ethyl
ethyl

methyl
H

13-pyridyl
13-pyridyl

+
-

-

ethyl

H

13-pyridyl

↓↓
No
Change
No
Change

-

-

H

ethyl

H

ethyl

ethyl
amine
methyl

2-F
3,4benzyl
2-NH 2
2-NO 2

ethyl
ethyl

2-CF 3
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Synthetic 1 (µM) 0
ptau
total tau
actin

3 10 30

Figure B.1. Synthetic racemic 1 reduces tau levels in a tauopathy cell model with
low µM potency. Representative western blot of lysates from HEK293T cells stably
overexpressing P301L tau (HEK P301L tau) treated with indicated concentrations of
synthetic 1 for 24 h.
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Figure B.2. (continued on next page) LC-MS spectra of 3 treated cell lysates. (A)
Total ion current (TIC) chromatogram of untreated sample, (B) TIC of vehicle sample and
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(C) TIC of the vehicle sample spiked with 3 at 300 µM. (D) Electrospray ionization (ESI)
positive mode spectrum of the peak at the retention time (RT) 3.91 min representing the
internal standard 3. (E) Overlaid extracted ion chromatogram (EIC) of 3 at m z-1 359.2 for
cell lysates from HEK P301L cells treated with 3 at 30 µM for 1, 6 and 24 h incubation.

Table B.1. Top activated and inactivated upstream regulators as determined by IPA
software. The upstream regulators are chemicals or molecules predicted by IPA to
explain the upregulated and downregulated genes observed in our dataset. Their
activation state is determined by examining the known targets of each upstream regulator
in our dataset and comparing those targets’ changes to expectations derived from IPA.
The p-value of overlap is a measure of statistical significance with respect to the upstream
regulator for our dataset and a reference set of molecules from IPA (which define the
molecules that could possibly have been upstream regulators). The p-value is calculated
with the right-tailed Fisher's Exact Test.
Table B.1 Top activated and inactivated upstream
regulators as determined by IPA software.
Upstream Regulator
Predicted p-value of
Activation overlap
State
sirolimus/rapamycin
Activated
4.19E-43
PDGF (family)
Activated
2.21E-06
miR-1 (and other miRNAs Activated
1.75E-05
w/seed GGAAUGU)
nitrofurantoin
Inhibited
6.40E-08
methapyrilene
Inhibited
4.38E-07
mono-(2Inhibited
1.44E-05
ethylhexyl)phthalate

Table B.2. Top canonical pathways as determined by IPA software. The canonical
pathways are well-characterized metabolic and cell signaling pathways established in
IPA. The p-value is a measure of statistical significance with respect to each canonical
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pathway for our dataset and a reference set of pathways from IPA (which define the
molecules that could possibly have been pathways). The p-value is calculated with the
right-tailed Fisher's Exact Test.
Table B.2 Top canonical pathways as
determined by IPA software.
Top Canonical Pathways
P-Value
EIF2 Signaling
9.95E50
Regulation of EIF4 and p70S6K
3.13ESignaling
24
mTOR Signaling
1.23E16

Table B.3. Upregulated or downregulated kinases as determined by IPA software.
Negative values represent downregulated kinases and positive values represent up
regulated kinases in in neuronal cells treated with 3 for 24 h relative to vehicle treated
cells. The relevance to tau column shows the sites at which the specific kinases are
known to phosphorylate tau.
Table B.3 Upregulated or downregulated kinases as determined by IPA software.
Fold
Symbol
Entrez Gene Name
Kinase Function
Relevance to
Chang
based on UniProt
tau
e
-1.064
TWF1
twinfilin actin-binding
protein tyrosine
Unknown/NA
protein 1
kinase 9
-1.063
MAPK1
mitogen-activated protein serine/threonine
pT153,
kinase 1
kinase
T175/181, S422,
S46, S212/214,
S199/S202/T205
, S396/404
-1.039
PRKAR1A protein kinase,
cAMP dependent
T231, S262,
regulatory, type I, alpha
protein kinase A
S212/214,
S199/S202/T205
-1.017
CSNK2A1 casein kinase 2, alpha 1
serine/threonine
S199/S205/T205
polypeptide
kinase
, S396/404
1.090
ALDH18A aldehyde dehydrogenase gluatmate 5-kinase
Unknown/NA
1
18 family, A1
activity
1.372
PKM
pyruvate kinase, muscle
ATP generating
Unknown/NA
kinase
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Table B.4 Crystal data and structure refinement for Racemic (2 and 3).
Identification code
CSmyR
Empirical formula
C 21 H 28 O 6
Formula weight
376.43
Temperature/K
99.98
Crystal system
monoclinic
Space group
P2 1 /c
a/Å
10.2863(7)
b/Å
18.1078(13)
c/Å
10.1523(7)
α/°
90.00
β/°
94.602(4)
γ/°
90.00
3
Volume/Å
1884.9(2)
Z
4
3
ρ calc g/cm
1.327
-1
0.792
µ mm
F(000)
808.0
3
Crystal size/mm
0.05 × 0.03 × 0.02
Radiation
CuKα (λ = 1.54178)
2Θ range for data collection/°
8.62 to 133.12
Index ranges
-11 ≤ h ≤ 12, -21 ≤ k ≤ 21, -12 ≤ l ≤ 12
Reflections collected
21398
Independent reflections
3327 [R int = 0.0463, R sigma = 0.0299]
Data/restraints/parameters
3327/0/266
2
Goodness-of-fit on F
1.034
Final R indexes [I>=2σ (I)]
R 1 = 0.0391, wR 2 = 0.0877
Final R indexes [all data]
R 1 = 0.0571, wR 2 = 0.0948
-3
Largest diff. peak/hole / e Å
0.32/-0.21
Table B.5 Crystal data and structure refinement for enantiopure 2.
Identification code
CS_pl_SmyR_thf_hex_0m
Empirical formula
C 98.91 H 133.82 O 24.1
Moiety formula
4(C 21 H 26 O 5 ), 3.73(C 4 H 8 O), 0.37(O)
Formula weight
1708.39
Temperature/K
100(2)
Crystal system
hexagonal
Space group
P6 1
a/Å
49.7851(12)
b/Å
49.7851(12)
c/Å
6.7498(2)
α/°
90.00
β/°
90.00
γ/°
120.00
90

Table B.5 (Continued)

Volume/Å3
Z
ρ calc g/cm3
µ mm-1
F(000)
Crystal size/mm3
Radiation
2Θ range for data collection/°
Index ranges
Reflections collected
Independent reflections
Data/restraints/parameters
Goodness-of-fit on F2
Final R indexes [I>=2σ (I)]
Final R indexes [all data]
Largest diff. peak/hole / e Å-3
Flack parameter

14488.4(7)
6
1.175
0.675
5520.0
0.5 × 0.03 × 0.02
CuKα (λ = 1.54178)
6.14 to 134.84
-59 ≤ h ≤ 58, -56 ≤ k ≤ 56, -7 ≤ l ≤ 7
75183
15952 [R int = 0.1407, R sigma = 0.1116]
15952/290/1242
1.038
R 1 = 0.0862, wR 2 = 0.2079
R 1 = 0.1303, wR 2 = 0.2372
0.45/-0.28
0.1(3)

Table B.6 Results of Bijvoet-Pair Analysis and Bayesian Statistics for
enantiopure 2.
Space Group P61
Wavelength 1.54178
Bijvoet Pairs 6574
Coverage ...
84
DiffCalcMax. 448.66
Outlier Crit 897.31
Sigma Crit.. 0.25
Select Pairs
3
Number Plus
1
Number Minus
2
Aver. Ratio 0.910
RC ......... 0.726
Normal Prob. Plot
Sample Size. 6395
Corr. Coeff. 1.000
Intercept .. 0.176
Slope ...... 0.906
Bayesian Statistics
Type ....... Gaussian
Select Pairs 6395
P2(true).... 1.000
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Table B.6 (Continued)

P3(true).... 0.937
P3(rac-twin) 0.063
P3(false) .. 0.2E-05
G .......... 0.8473
G (su) ..... 0.3583
Hooft y .... 0.08
Hooft (su) . 0.18
Table B.7 Crystal data and structure refinement for 13.
Identification code
MYR_R16_6_0m
Empirical formula
C 21 H 26 O 5
Moiety Formula
C 21 H 24 O 4 , H 2 O
Formula weight
358.42
Temperature/K
99.99
Crystal system
tetragonal
Space group
I4 1 /a
a/Å
22.3255(10)
b/Å
22.3255(10)
c/Å
14.2555(7)
α/°
90
β/°
90
γ/°
90
3
Volume/Å
7105.3(7)
Z
16
3
ρ calc g/cm
1.340
μ mm-1
0.771
F(000)
3072.0
Crystal size/mm3
0.18 × 0.15 × 0.14
Radiation
CuKα (λ = 1.54178)
2Θ range for data collection/° 7.358 to 145.338
Index ranges
-27 ≤ h ≤ 27, -25 ≤ k ≤ 27, -17 ≤ l ≤ 17
Reflections collected
21368
Independent reflections
3529 [R int = 0.0537, R sigma = 0.0348]
Data/restraints/parameters
3529/4/254
2
Goodness-of-fit on F
1.027
Final R indexes [I>=2σ (I)]
R 1 = 0.0445, wR 2 = 0.1166
Final R indexes [all data]
R 1 = 0.0529, wR 2 = 0.1231
Largest diff. peak/hole / e Å-3 0.30/-0.23
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B.10 Supplementary Methods
B.10.1 Compound Synthesis
4-(4-Benzyloxy-3-iodophenyl)butan-2-one (8). To a stirring suspension of 4-(4benzyloxy-phenyl)butan-2-one (7) (25.0 g, 98.4 mmol) in chloroform (150 mL) was added
silver trifluoracetate (25.0 g, 113 mmol). A solution of iodine (28.7 g, 113 mmol) in
chloroform (750 mL) was added dropwise over 2 h. After complete addition, the reaction
was allowed to stir for 16 h after which the mixture was filtered and the filtrate was washed
with saturated aqueous sodium thiosulfate (250 mL). The organic phase was dried over
magnesium sulfate, filtered and concentrated at reduced pressure. The resulting crude
product was purified through silica gel (300 g cartridge) eluting with a gradient of 0 to 40%
ethyl acetate in hexanes. The pure fractions were combined and concentrated at reduced
pressure to give 3 as a tan solid (24.0 g, 64%). 1H NMR (300 MHz, CDCl 3 ) δ 7.62 (d, J=
2.1 Hz, 1H), 7.51-7.45 (m, 2H), 7.42-7.28 (m, 3H), 7.08 (dd, J= 2.1, 8.2 Hz, 1H), 6.76 (d,
J= 8.2 Hz, 1H), 5.11 (s, 2H), 2.82-2.68 (m, 4H), 2.13 (s, 3H). LRMS (ESI) [M+H]+ m z-1
381.0.
4-[4-Benzyloxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]butan2-one (9). A stirring solution of 8 (10.0 g, 26.3 mmol), bis(pinacolato)diboron (8.0 g, 31.5
mmol) and potassium acetate (7.75 g, 79.0 mmol) in anhydrous dimethyl sulfoxide (100
mL) was degassed with nitrogen for 10 min. 1,1'-Bis(diphenylphosphino)ferrocenepalladium(II)dichloride dichloromethane complex (2.15 g, 2.63 mmol) was added and the
resulting suspension was heated at 80 °C for 2 h. The reaction mixture was cooled to
ambient temperature and water (500 mL) was added. The mixture was extracted with
ethyl acetate (3 x 350 mL). The organic extracts were combined, dried over magnesium
sulfate, filtered and concentrated at reduced pressure. The resulting crude product was
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purified through silica gel (300 g cartridge) eluting with a gradient of 0 to 20% ethyl acetate
in hexanes. The pure fractions were combined and concentrated at reduced pressure to
give 9 as a white solid (6.2 g, 62%). 1H NMR (300 MHz, CDCl 3 ) δ = 7.60 (d, J= 7.3 Hz,
1H), 7.59 - 7.57 (m, 1H), 7.50 (d, J= 2.3 Hz, 1H), 7.39 - 7.25 (m, 4H), 7.21 (dd, J= 2.5,
8.4 Hz, 1H), 6.85 (d, J= 8.5 Hz, 1H), 5.09 (s, 2H), 2.87 - 2.81 (m, 2H), 2.76 - 2.70 (m, 2H),
2.13 (s, 3H), 1.56 (s, 1H), 1.37 (s, 12H). LRMS (ESI) [M+H]+ m z-1 381.3.
3-(2-Benzyloxy-3,4-dimethoxyphenyl)propionaldehyde (5). A stirring solution
of 2-benzyloxy-1-bromo-3,4-dimethoxybenzene (4) (16 g, 49.5 mmol), allyl alcohol (3.70
mL, 54.4 mmol), N-methyldicyclohexylamine (11.7 mL, 54.4 mmol), 2-(di-tert-butylphosphanyl)-1-phenyl-1H-indole (1.00 g, 2.96 mmol) in DMF (192 mL) was degassed with
nitrogen for 10 min. Bis(dibenzylideneacetone)palladium(0) (571 mg, 0.99 mmol) was
added and the resulting suspension was heated at 100 °C for 3 h. The reaction mixture
was cooled to ambient temperature and poured into dilute hydrochloric acid (0.5 N, 500
mL). The mixture was extracted with ethyl acetate (3 x 250 mL). The organic extracts
were combined, dried over magnesium sulfate, filtered and concentrated at reduced
pressure. The resulting crude product was purified through silica gel (180 g cartridge)
eluting with a gradient of 0 to 20% ethyl acetate in hexanes. The pure fractions were
combined and concentrated at reduced pressure to give 5 as an amber oil (6.2 g, 53%). 1H
NMR (300 MHz, CDCl 3 ) δ = 9.69 (s, 1H), 7.46 - 7.31 (m, 5H), 6.86 - 6.78 (m, J= 8.5 Hz,
1H), 6.66 - 6.59 (m, J= 8.5 Hz, 1H), 5.09 (s, 2H), 3.89 (s, 3H), 3.86 (s, 3H), 2.82 (t, J= 7.5
Hz, 2H), 2.61 (t, J= 7.2 Hz, 2H). LRMS (ESI) [M+H]+ m z-1 301.2.
3-(2-Benzyloxy-5-iodo-3,4-dimethoxyphenyl)propionaldehyde

(6).

To

a

stirring suspension of 3-(2-benzyloxy-3,4-dimethoxy-phenyl)propionaldehyde (5) (7.0 g,
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23.3 mmol) in chloroform (50 mL) was added silver trifluoracetate (5.66 g, 25.6 mmol). A
solution of iodine (6.5 g, 25.6 mmol) in chloroform (250 mL) was added dropwise over 2
h. After complete addition, the reaction was allowed to stir for 16 h after which the mixture
was filtered and the filtrate was washed with saturated aqueous sodium thiosulfate (150
mL). The organic phase was dried over magnesium sulfate, filtered and concentrated at
reduced pressure. The resulting crude product was purified through silica gel (180 g
cartridge) eluting with a gradient of 0 to 30% ethyl acetate in hexanes. The pure fractions
were combined and concentrated at reduced pressure to give 6 as a tan oil (7.3 g,
74%). 1H NMR (300 MHz, CDCl 3 ) δ = 9.70 (s, 1H), 7.44 - 7.33 (m, 5H), 7.29 (s, 1H), 5.07
(s, 2H), 3.92 (s, 3H), 3.87 (s, 3H), 2.81 - 2.74 (m, 2H), 2.64 - 2.56 (m, 2H). LRMS (ESI)
[M+H]+ m z-1 427.1.
7-(2-Benzyloxy-5-iodo-3,4-dimethoxyphenyl)-1-[4-benzyloxy-3-(4,4,5,5tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]hept-4-en-3-one (10). To a solution of
diisopropylamine (0.81 mL, 5.76 mmol) in tetrahydrofuran (20 mL) under nitrogen at 0 °C
was added n-butyllithium (2.5 M in hexanes, 2.2 mL, 5.5 mmol). After 15 min, the mixture
was cooled to -78 °C and a solution of 9 (2.0 g, 5.24 mmol) in tetrahydrofuran (20 mL)
was added dropwise over 15 min. After 45 min, a solution of 6 (2.14 g, 5.0 mmol) in
tetrahydrofuran (20 mL) was added dropwise over 15 min. After 45 min, the reaction
mixture was poured into saturated aqueous ammonium chloride (100 mL) and the mixture
was allowed to warm to ambient temperature. The mixture was poured into water and
was extracted with ethyl acetate (3 x 75 mL). The organic extracts were combined, dried
over magnesium sulfate, filtered and concentrated at reduced pressure. The crude
product was dissolved in toluene (60 mL), p-toluenesulfonic acid (100 mg) was added
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and the mixture was heated at 90 °C for 3 h. The mixture was cooled to ambient
temperature, diluted with ethyl acetate (75 mL) and extracted with saturated aqueous
sodium hydrogen carbonate (50 mL). The organic extract was dried over magnesium
sulfate, filtered and concentrated at reduced pressure. The resulting crude product was
purified through silica gel (80 g cartridge) eluting with a gradient of 0 to 30% ethyl acetate
in hexanes. The pure fractions were combined and concentrated at reduced pressure to
give 10 as a colorless oil (1.55 g, 39% over 2 steps). 1H NMR (300 MHz, CDCl 3 ) δ = 7.59
(d, J= 7.3 Hz, 2H), 7.45 - 7.30 (m, 1H), 7.28 - 7.25 (m, 9H), 7.20 (dd, J= 2.3, 8.4 Hz, 1H),
6.85 (d, J= 8.5 Hz, 1H), 6.74 (td, J= 6.8, 15.8 Hz, 1H), 6.01 (d, J= 15.8 Hz, 1H), 5.09 (s,
2H), 5.04 (s, 2H), 3.90 (s, 3H), 3.88 (s, 3H), 2.85 - 2.73 (m, 4H), 2.68 - 2.53 (m, 2H), 2.35
(q, J= 7.5 Hz, 2H), 1.36 (s, 12H). LRMS (ESI) [M+H]+ m z-1 789.3.
3,15-Bis-benzyloxy-16,17-dimethoxy-tricyclo[12.3.1.12,6]nonadeca1(18),2,4,6(19),10,14,16-heptaen-9-one (11). A stirring solution of 10 (1.40 g, 1.78
mmol), and potassium acetate (579 mg, 6.0 mmol) in anhydrous dimethyl sulfoxide (177
mL) was degassed with nitrogen for 10 min. 1,1'-Bis(diphenylphosphino)ferrocenepalladium(II)dichloride dichloromethane complex (150 mg, 0.18 mmol) was added and
the resulting suspension was heated at 80 °C for 2 h. The reaction mixture was cooled to
ambient temperature and water (700 mL) was added. The mixture was extracted with
ethyl acetate (3 x 350 mL). The organic extracts were combined, dried over magnesium
sulfate, filtered and concentrated at reduced pressure. The resulting crude product was
purified through silica gel (80 g cartridge) eluting with a gradient of 0 to 20% ethyl acetate
in hexanes. The pure fractions were combined and concentrated at reduced pressure to
give 11 as a white solid (207 mg, 22%). 1H NMR (300 MHz, CDCl 3 ) δ = 7.59 (d, J= 8.5
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Hz, 1H) 7.52 - 7.47 (m, 2H), 7.45 - 7.26 (m, 8H), 7.05 (dd, J= 2.3, 8.5 Hz, 1H), 6.94 - 6.80
(m, 2H), 6.54 (s, 1H), 6.39 (d, J= 15.5 Hz, 1H), 5.13 (br. s, 2H), 5.05 (br. s, 2H), 3.96 (s,
3H), 3.79 (s, 3H), 3.22 -3.05 (m, 3H), 2.85 - 2.72 (m, 2H), 2.70 - 2.49 (m, 3H). LRMS (ESI)
[M+H]+ m z-1 535.2.
3,15-Dihydroxy-16,17-dimethoxy-tricyclo[12.3.1.12,6]nonadeca1(18),2,4,6(19),14,16-hexaen-9-one (myricanone, 12). A suspension of palladium on
carbon (10%, 160 mg) in acetic acid (6 mL) was added a solution of 11 (182 mg) in acetic
acid (10 mL). This suspension was shaken on a Parr apparatus under hydrogen (55 psi)
for 20 h. The mixture was filtered through Celite, the bottle and filter cake was rinsed with
methanol and the combined filtrates were concentrated at reduced pressure. The crude
product was purified through silica gel (20 g cartridge) eluting with a gradient of 0 to 40%
ethyl acetate in hexanes. The pure fractions were combined and concentrated at reduced
pressure to give 12 as an oil which solidified on standing to a white solid (75 mg, 61%). 1H
NMR (300 MHz, CDCl 3 ) δ = 7.64 (s, 1H), 7.05 (dd, J= 2.2, 8.1 Hz, 1H), 6.88 (d, J= 8.2
Hz, 1H), 6.74 (d, J= 2.1 Hz, 1H), 6.61 (s, 1H), 5.83 (s, 1H), 3.99 (s, 3H), 3.81 (s, 3H), 3.07
- 2.97 (m, 2H), 2.83 - 2.70 (m, 6H), 1.98 - 1.82 (m, 4H). LRMS (ESI) [M+H]+ m z-1 357.2.
16,17-Dimethoxy-tricyclo[12.3.1.12,6]nonadeca-1(18),2,4,6(19),14,16hexaene-3,9,15-triol (synthetic myricanol, 1). To a solution of myricanone (12) (75 mg,
0.21 mmol) in tetrahydrofuran (4 mL) under nitrogen at -78 °C was added dropwise a
solution of K-Selectride (1.0 M in THF, 0.84 mL, 0.84 mmol) and the reaction was allowed
to warm to ambient temperature over 1 h. The reaction mixture was diluted with saturated
aqueous ammonium chloride (15 mL) and extracted with ethyl acetate (3 x 25 mL). The
combined organic extracts were dried over magnesium sulfate, filtered and concentrated
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at reduced pressure. The crude product was purified through silica gel (12 g cartridge)
eluting with a gradient of 0 to 50% ethyl acetate in hexanes. The pure fractions were
combined and concentrated at reduced pressure to give 1 (60 mg, 80%). 1H NMR (300
MHz, CDCl 3 ) δ = 7.66 (s, 1H), 7.19 (d, J= 2.0 Hz, 1H), 7.10 (dd, J= 2.2, 8.2 Hz, 1H), 6.91
(s, 1H), 6.90 (d, J= 8.2 Hz, 1H), 5.82 (br. s, 1H), 4.16 - 4.06 (m, 1H), 4.00 (s, 3H), 3.88
(s, 3H), 2.94 – 2.85 (m, 2H), 2.81 (dt, J= 18, 2.4 Hz, 1H), 2.62 - 2.50 (m, 1H), 2.41 - 2.28
(m, 1H), 2.00 - 1.88 (m, 3H), 1.76 - 1.66 (m, 2H), 1.62 - 1.52 (m, 3H). LRMS (ESI)
[M+H]+ m z-1 359.1.
(11S)‐4,5‐Dimethoxytetracyclo[9.7.1.02,7.015,19]nonadeca‐
1(18),2(7),3,5,15(19),16‐hexaene‐6,18‐diol (13). Myricanol (1) (50 mg) was treated in a
solution of 10 mL of toluene with 79 mg of para toluene sulfonic acid. The solution was
boiled for 24 h, cooled, diluted with hexane, washed successively with saturated solutions
of NaHCO 3 and NaCl, dried over MgSO 4 , and evaporated. The mixture was first purified
by HPLC using normal phase with 3% ethyl acetate/hexane. The second fraction was
separated using the same reverse phase condition and provided 21 mg of 13.
White powder; [α] D 21= 0.0 (c = 0.1, chloroform); UV (MeOH) λ max 286, 244 nm; IR (ATR,
thin film) 3443, 2933, 2864, 1655, 1581, 1510, 1469, 1424, 1361, 1268, 1245, 1141, 1115,
735 cm-1; 1H NMR (600 MHz, CDCl 3 ) δ = 7.04 (H16, d, J= 8.3 Hz, 1H), 6.82 (H15, d, J=
8.3 Hz, 1H), 6.35 (H2, s, 1H), 6.04 (5-OH, s, 1H), 4.99 (17-OH, brs, 1H), 3.98 (H21, s,
3H), 3.83 (H20, s, 3H), 3.01 (H7b, dd, J= 13.2, 8.0 Hz, 1H), 2.89 (H13b, ddd, J= 16.8,
8.0, 2.7 Hz, 1H), 2.80 (H13a, ddd, J= 17.3, 10.0, 8.0 Hz, 1H), 2.42 (H10, dt, J= 9.5, 3.1
Hz, 1H), 1.99 (H12b, m, 1H), 1.97 (H8b, m, 1H), 1.86 (H7a, m, 1H), 1.72 (H12a, m, 1H),
1.65 (H9, m, 2H), 1.60 (H11, m, 2H), 1.46 (H8a, m, 1H); 13C NMR (125 MHz, CDCl 3 ) δ =
98

150.0 (C3), 149.9 (C17), 147.6 (C5), 142.8 (C18), 135.1 (C4), 130.1 (C16), 129.1 (C19),
126.9 (C14), 125.1 (C1), 124.3 (C6), 112.5 (C15), 104.0 (C2), 61.0 (C21), 55.8 (C20),
37.1 (C9), 34.3 (C10), 31.9 (C11), 27.5 (C8), 27.3 (C13), 25.2 (C7), 16.9 (C12). 70 eV
HRMS (EI) [M+] m z-1 340.1653 (calcd for C 21 H 24 O 4 340.1675). White powder recrystallized as colorless needles from acetonitrile/ water at room temperature.
Crystallographic data for 13 registered as CCDC #1026945) can be obtained free of
charge

from

The

Cambridge

Crystallographic

Data

Centre

via www.ccdc.cam.ac.uk/data_request/cif.
6,18-Dihydroxy-4,5-dimethoxytricyclo[13.3.1.02,7]nonadeca1(18),2(7),3,5,15(19),16-hexaen-12-one (isomyricanone, 15). Myricanone (12, 41 mg,
1.15 mmol) was added to boron trifluoride diethyl etherate (2.7 mL) under nitrogen and
the reaction was heated at 45 °C for 48 h. The reaction mixture was cooled to ambient
temperature and poured into water (25 mL). The aqueous layer was extracted with diethyl
ether (3 x 25 mL) and the combined organic extracts were dried over magnesium sulfate,
filtered and concentrated at reduced pressure. The crude product was purified through
silica gel (4 g cartridge) eluting with a gradient of 0 to 25% ethyl acetate in hexanes. The
pure fractions were combined and concentrated at reduced pressure to give 15 as a white
solid (24 mg, 59%). 1H NMR (300 MHz, CDCl3) δ = 7.13 (dd, J =8.4, 2.2 Hz, 1H), 7.11
(d, J =8.4 Hz, 1H), 6.79 (d, J =2.3 Hz, 1H), 6.39 (s, 1H), 5.96 (s, 1H), 4.85 (s, 1H), 3.95
(s, 3H), 3.84 (s, 3H), 3.02 (dt, J =3.4, 13.0 Hz, 1H), 2.80 (tt, J =13.5, 4.2 Hz, 1H), 2.57 (dt,
J =3.4, 13.0 Hz, 1H), 2.41 (m, 2H), 2.11 (m, 2H), 1.95 (m, 2H), 1.75 (dt, J =2.7, 12.3 Hz,
1H), 1.39 (m, 1H), 1.13 (m, 1H). 13C NMR (75 MHz, CDCl 3 ) δ = 213.5, 151.4, 50.4, 148.8,
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135.4, 132.1, 130.6, 130.4, 129.1, 126.8, 122.4, 116.1, 104.5, 61.1, 56.0, 44.6, 42.8, 33.4,
26.9, 25.1, 21.0.
4,5-Dimethoxy-tricyclo[13.3.1.02,7]nonadeca-1(18),2(7),3,5,15(19),16hexaene-6,12,18-triol (isomyricanol, 16). To a solution of isomyricanone (15, 20 mg,
0.056 mmol) in methanol (0.60 mL) was added sodium borohydride (13 mg, 0.337 mmol)
under nitrogen and the reaction was stirred at ambient temperature for 1 h. The reaction
mixture was then quenched with water (15 mL) and the aqueous layer was extracted with
ethyl acetate (3 x 20 mL). The combined organic extracts were dried over magnesium
sulfate, filtered and concentrated at reduced pressure to give the product as a white solid
(18 mg, 89%). 1H NMR (300 MHz, CDCl 3 ) δ = 7.05 (dd, J= 8.4, 2.3 Hz, 1H), 6.94 (d, J=
8.4 Hz, 1H), 6.89 (d, J= 2.1 Hz, 1H), 6.45 (s, 1H), 5.98 (s, 1H), 4.72 (s, 1H), 3.95 (m, 3H),
3.84 (s, 3H), 3.69 (t, J= 8.8 Hz, 1H), 2.85 (tt, J= 13.4, 4.0 Hz, 1H), 2.66 (dt, J= 3.5, 13.1
Hz, 1H), 2.48 (m, 1H), 1.95 (tt, J= 13.5, 4.0 Hz, 1H), 1.89-1.43 (m, 5H), 1.32 (m, 1H), 1.14
(m, 1H), 0.92 (m, 1H), 0.66 (br t, J= 12.1 Hz, 1H). 13C NMR (75 MHz, CDCl 3 ) δ = 151.1,
150.4, 148.6, 135.4, 133.0, 131.5, 131.1, 129.3, 126.7, 122.5, 115.9, 104.6, 72.4, 61.1,
56.0, 40.1, 35.2, 33.8, 26.7, 25.4, 24.0. HRMS (EI) [M+] m z-1 358.1823 (calcd for
C 21 H 26 O 5 348.1780)

B.10.2 Chiral Separation
Racemic myricanol (1) ([α] D 20= +46.4) was separated by HPLC using a chiral
column under solvent system 1 and the separation yielded 2 fractions eluting at 30.9 min
and 47.4 min, corresponding to 2 [α] D 22= +55.0 (c = 1.0, chloroform) and 3 [α] D 22= -55.0
(c = 1.0, chloroform). The scalemic 1 was dissolved in warm ethanol/ water then slowly
cooled in the freezer at -20oC to provide high quality co-crystal needles wherein the co100

former molecules are enantiomers 2 and 3. Racemic 13 was separated by HPLC using a
chiral under solvent system 2 and the separation yielded 2 fractions eluting at 25.8 min
and 29.8 min, corresponding to (-)-13 [α] D 20= - 93.8 (c = 0.08, chloroform) and (+)-13
[α] D 20= +100 (c = 0.09, chloroform). And the pure enantiomer 2 was recrystallized from
terahydrofuran/ hexane at 4oC. Crystallographic data for the racemic mixture 1
(enantiomers 2/ 3 [1:1]) and the pure enantiomer 2 (registered as CCDC #1026943 and
CCDC #1026944, respectively) can be obtained free of charge from The Cambridge
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

B.10.3 X-ray crystallography
The X-ray diffraction data for the racemic (2 and 3), the pure enantiomer 2, and
the racemic 13 were measured on a Bruker D8 Venture PHOTON 100 CMOS system
equipped with a CuKα INCOATEC Imus micro-focus source (λ = 1.54178 Å). Indexing
was performed using APEX21 (Difference Vectors method). Data integration and
reduction were performed using SaintPlus 6.01.2 Absorption correction was performed by
multi-scan method implemented in SADABS.3 Space groups were determined using
XPREP implemented in APEX2.1 The structure was solved using SHELXS-97 (direct
methods) and refined using SHELXL-97
APEX2,1,

4

WinGX v1.70.01

4-7

4

(full-matrix least-squares on F2) contained in

and OLEX2.4,

8

All non-hydrogen atoms were refined

anisotropically. Hydrogen atoms of –CH, -CH 2 and -CH 3 groups were placed in
geometrically calculated positions and included in the refinement process using riding
model with isotropic thermal parameters: Uiso(H) = 1.2(1.5)Ueq(-CH,-CH 2 (-CH 3 )).
Racemic (2 and 3): Hydrogen atoms of water molecule and hydroxyl groups have
been found from difference Fourier map and were freely refined. The remaining hydrogen
101

atoms were placed in geometrically calculated positions and included in the refinement
process using riding model with isotropic thermal parameters: Uiso(H) = 1.2Ueq(-CH, CH 2 ) and Uiso(H) = 1.5Ueq(-CH 3 ). Crystal data and refinement conditions are shown in
Table B.7.
Enantiopure 2: Disordered THF molecules that are located in the structural voids
have been refined using geometry and ADP restraints. Additionally the occupancy of
disordered THF molecules has been refined as free variable for all but one disordered
THF for which it was set to be 0.25. The hydrogen atoms were placed in geometrically
calculated positions and included in the refinement process using riding model with
isotropic thermal parameters: Uiso(H) = 1.2Ueq(-CH, -CH 2 ) and Uiso(H) = 1.5Ueq(-CH 3 ).
There are four molecules of myricanol in asymmetric unit. The absolute configuration has
been additionally verified by Bijvoet-Pair Analysis and Bayesian Statistic method
implemented in program Platon,9, 10 in which the value of P2(true) gives the probability
(scale 0 to 1) that the current absolute structure is the correct one, assuming that the
compound is enantiopure. As can be seen from Table B.9 the P2 parameter equals 1
suggesting the absolute configuration of the molecule is correct. Crystal data and
refinement conditions are shown in Table B.8.
Racemic 13: Hydrogen atoms of water molecules have been found from difference
Fourier map and were refined using distance restraint and with Uiso(H) = 1.5Ueq(OH 2 O).
One hydrogen atom of water molecule is disordered over two positions. Crystal data and
refinement conditions are shown in Table B.9.

B.10.4 SILAC sample preparation and analysis
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Trypsin digestion: Samples were digested using a modified version of the filter
aided sample preparation (FASP) method.11 Briefly, equal amounts of protein extract from
each biological replicate were combined and diluted to ≤ 0.5% SDS in 8 M urea, 50 mM
ammonium bicarbonate (AmBic). Samples were loaded onto 30 kDa molecular weight
cutoff filters (Expedeon, San Diego, CA, USA) for buffer exchange to 8 M urea, 50 mM
AmBic prior to alkylation of Cys residues by addition of iodoacetamide to 10 mM and
incubation in the dark for 20 min at RT. Alkylation buffer was exchanged to 50 mM AmBic
prior to addition of Promega (Madison, WI, USA) sequencing grade trypsin at a ratio of
1:50 trypsin:protein. Digestions were performed by incubation at 37 °C overnight (16 – 20
h). Trypsin activity was halted by addition of formic acid to 1% v/v.
Desalting of digests: Desalting of peptide suspensions was performed on
MacroSpin 300 Å C18 solid-phase extraction (SPE) spin columns (The Nest Group, Inc.,
Southborough, MA, USA) followed by “speed-vac” centrifugal vacuum concentration at
50°C (Labconco, Kansas City, MO, USA). Samples were resuspended in 0.1% formic
acid in water to a final concentration of 1 mg mL-1 for HPLC-MS/MS analysis.
High-performance liquid chromatography-tandem mass spectrometric (HPLCMS/MS) analysis: Each duplex SILAC replicate was separated by nano-flow reversedphase HPLC on an Eksigent NanoLC 1D Plus system (Dublin, CA, USA). Five
micrograms of each replicate was loaded onto a New Objective (Woburn, MA, USA) 150
μm i.d. × 2.5 cm C 18 capillary trap (5 µm particle, 300Å pore). Peptide ions were then
transferred to and eluted from a CMP Scientific (Hoboken, NJ, USA) 75 μm i.d. × 10 cm
analytical column with C 18 on 5 μm silica beads with 300 Å pores by linear gradient of 2%
- 40% acetonitrile, 0.1% formic acid over 180 min at a flow rate of 300 nL × min-1. Eluates
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were delivered by electrospray ionization (ESI) at 2.5 kV and analyzed in positive ion
mode on a hybrid linear ion trap-orbitrap mass spectrometer (LTQ XL Orbitrap, Thermo
Scientific, San Jose, CA, USA) equipped with XCalibur (version 2.0.7) data acquisition
software. Full MS scans were performed on m z-1 300 – 2000 at 60,000 resolution (FT
analyzer) followed by data-dependent tandem MS (MS/MS) scans of the top-ten most
intense precursor ions in the linear ion trap. Dynamic exclusion duration was set for 30 s
with one repeat, a list size of 500, and a mass width of ± 10 ppm. Raw MS/MS spectral
data were searched against a UniProt human FASTA database (148254 entries) including
randomized and reversed sequences using MaxQuant version 1.3.0.5 (Max Planck
Institute of Biochemistry, Martinsreid, Germany)12 Cys carbamidomethylation was
selected as a fixed modification and Acetyl-protein N-terminus and Met-oxidation were
selected as variable modification. Tryptic peptide pairs identified with a monoisotopic
mass of 8 Da (Lys) or 10 Da (Arg) were selected for quantitation. Precursor FTMS
tolerance was set for 6 ppm with ion trap tolerance set for 0.5 Da. Identification thresholds
for both peptide and protein identifications were specified for ≤ 1 % false-discovery rate
(FDR).

B.10.5 Liquid Chromatography Mass Spectrometry (LC-MS)
HEK293T P301L Cells were treated with 30 µM of 3 for 1, 6 and 24 h. Cells were
lysed and harvested as described in cell culture section of the methods. One vehicle
sample was spiked with a 10x concentration (300 µM) of 3 and used as positive control.
Each cell lysate was first treated by a 5-minute centrifugation time at 14,000 g. The
supernatant was then filtrated through a Hydrosart membrane (30,000 MWCO) during a
15-minute centrifugation time at 14,000 g and 10 µL of the resulting filtrate was injected
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on Agilent 1100 series LC-MS 6120 single quadrupole (LRESIMS) using a Phenomenex
Kinetex C18 (2.6 µm, 3.0 x 50 mm) at 30oC under a linear gradient condition of 10% 100% ACN aq (+0.05% Formic acid) over 7 min, finishing at 100% ACN aq (+0.05% Formic
acid) over 3 min at a flow rate of 1 mL × min-1. A full scan was performed on m z-1 1001000 amu for data acquisition using the Chemstation software and Mass Hunter software
was used for data analysis.
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APPENDIX C:
Supporting Information for Chapter Three

Concentration (µM) Rhodacyanine
Phenothiazine

3

Tau

Adeonisine analog
Hydroxytyrosol
Actin (Rep)
Figure C.1. Effects of Select Tau Modulating Compounds on P301L Tau stably
transfected HEK293T Cells. Cells were treated with indicated concentrations of each
compound or vehicle (-) for 24 h. Lysates were analyzed by western blot for tau and actin
levels. A representative blot is shown for actin.
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Figure C.2. Rhodacyanine does not significantly alter hydrogen peroxide
production in the presence of tau, suggesting that cysteine oxidation is not
occurring. Recombinant human P301L tau was incubated with compound for 1 h and
levels of hydrogen peroxide were measured. Values are shown ± SEM.
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Figure C.3. Hsp70 inhibitor compounds that also reduce tau aggregation are the
most potent tau lowering agents. Correlation analyses comparing % tau lowering and
% tau aggregation inhibition were performed for all Hsp70 inhibitors. A positive correlation
was demonstrated between these two variables as determined by R square values after
linear regression.
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